The storylines故事线
Click a development’s source links to open the original article.点击进展下方的来源链接可打开原文。
Executive leadership changes高管人事变动
20 · 2024-01-02 → 2026-07-01
▾
A series of resignations, promotions, and board reshuffles at the executive and board level.一系列高管及董事会层面的辞职、晋升与改组。
2024-01-02Executive President Mei Jingping retired effective Jan 1, 2024.执行总裁梅璟萍自2024年1月1日起因到龄退休离任。
2024-01-17Vice President Yuan Ning resigned for personal reasons, effective Jan 17, 2024.副总裁袁宁因个人原因辞任，自2024年1月17日起生效。
2024-01-17Feng Rongli and Li Jing promoted from Senior Vice Presidents to Executive Presidents, effective Jan 17, 2024.冯蓉丽、李静由高级副总裁晋升为执行总裁，自2024年1月17日起生效。
2024-02-01Zhang Yuejian resigned as Vice President of Fosun Pharma due to personal reasons, effective from February 1, 2024.张跃建因个人原因辞去复星医药副总裁职务，自2024年2月1日起生效。
2024-06-19Fosun Pharma's supervisory board chair Ren Qian resigned due to retirement; Wang Lina elected as new employee supervisor.复星医药监事会主席任倩因到龄退休辞职；王丽娜当选为职工监事。
2024-07-01Non-executive director Yao Fang and Vice President Xu Aihua resigned due to work changes and personal reasons respectively, effective June 30, 2024.非执行董事姚方因工作变动、副总裁徐爱华因个人原因分别辞职，自2024年6月30日起生效。
2024-09-13Executive President Li Shengli resigned due to personal reasons, effective September 13, 2024.高级管理人员李胜利因个人原因辞去执行总裁职务，自2024年9月13日起生效。
2025-04-02Senior Vice President Bao Qingui resigns for personal reasons, becoming the 6th senior executive to leave since 2024.高级副总裁包勤贵因个人原因辞职，成为自2024年以来第6位离职的高管。
2025-04-23Senior Vice President Li Dongjiu resigns due to reaching retirement age, effective April 23, 2025.高级副总裁李东久因到龄退休辞职，自2025年4月23日起生效。
2025-04-29Board reshuffle: Wu Yifang resigns as Chairman, becomes non-executive director; Chen Yuqing appointed as Chairman; Guan Xiaohui becomes Co-Chairman; Wen Deyong becomes Vice Chairman.董事会调整：吴以芳辞任董事长改任非执行董事，陈玉卿任董事长，关晓晖任联席董事长，文德镛任副董事长。
2025-05-06Board reshuffle: Wu Yifang stepped down as executive director and chairman, became non-executive director; Chen Yuqing appointed as chairman and executive director; Guan Xiaohui appointed as co-chairman; Wen Deyong appointed as vice chairman.董事会调整：吴以芳不再担任执行董事、董事长，改任非执行董事；陈玉卿担任董事长、执行董事；关晓晖担任联席董事长；文德镛担任副董事长。
2025-05-20Senior Vice President Rong Yang resigned for personal reasons, effective May 16, 2025.高级副总裁Rong Yang因个人原因辞任，自2025年5月16日起生效。
2025-06-07Fosun Pharma elected Yan Jia as employee representative director for the 10th board; she serves as co-CFO and president assistant.复星医药选举严佳为第十届董事会职工董事，现任联席首席财务官、总裁助理。
2025-06-24Fosun Pharma elected new board: Chen Yuqing as Chairman, Guan Xiaohui as Co-Chairman, Wen Deyong as Vice Chairman; appointed Liu Yi as CEO and President.复星医药选举陈玉卿为董事长、关晓晖为联席董事长、文德镛为副董事长；聘任刘毅为首席执行官兼总裁。
2025-10-01Wu Yifang resigned as non-executive director of Fosun Pharma, effective Sep 30, 2025; Liu Yi nominated as executive director candidate.吴以芳辞去复星医药非执行董事职务，自2025年9月30日生效；提名刘毅为执行董事候选人。
2025-10-09Wu Yifang appointed Executive Operating Partner at CBC Group (康桥资本).吴以芳被任命为康桥资本执行运营合伙人。
2025-10-10Wu Yifang appointed Chairman of the Board of Everest Medicines (云顶新耀, 01952.HK).吴以芳被任命为云顶新耀董事会主席。
2026-01-27Fosun Pharma appointed Meng Lingyuan as Vice President, effective January 26, 2026; she holds a bachelor's degree from Shanghai University of Finance and Economics and is a CPA.复星医药聘任孟凌媛为公司副总裁，任期自2026年1月26日起；她拥有上海财经大学学士学位及中国注册会计师资质。
2026-04-02CFO Chen Zhanyu resigned effective April 2, 2026, remaining as senior VP; Huang Zhi appointed as new senior VP and CFO, effective same day, with prior roles at Novartis, BeiGene, and Ascentage Pharma.首席财务官陈战宇于2026年4月2日辞任，留任高级副总裁；黄智同日被聘任为高级副总裁、首席财务官，此前任职于诺华制药、百济神州和亚盛医药。
2026-07-01Fosun Pharma promoted Xingli Wang from Co-President to President, effective July 1, 2026; CEO Liu Yi stepped down as President but remains CEO.复星医药晋升王兴利为总裁，自2026年7月1日起生效；首席执行官刘毅不再兼任总裁，但仍任CEO。
Serplulimab (Hansizhuang) global expansion斯鲁利单抗（汉斯状）全球拓展
16 · 2024-01-02 → 2026-08-03
▾
Global development and commercialization of the anti-PD-1 mAb serplulimab, including US/EU approvals and licensing deals.抗PD-1单抗斯鲁利单抗的全球开发和商业化，包括美国/欧盟获批及许可交易。
2024-01-02Hansizhuang (serplulimab injection) bridging trial for ES-SCLC started in US; US commercial team under construction; exclusive rights licensed to Intas for Europe/India (up to €185M) and to KGbio for Southeast Asia/MENA (upfront $10M+$7M).汉斯状（斯鲁利单抗注射液）在美国启动ES-SCLC桥接实验并自建商业化团队；授权Intas在欧洲/印度独家权益（至多1.85亿欧元），授权KGbio在东南亚/中东北非权益（首付1000万+700万美元）。
2024-08-15Fosun Pharma's serplulimab injection (Han Si Zhuang) MAA for ES-SCLC first-line treatment remains under EMA review since March 2023.复星医药斯鲁利单抗注射液（汉斯状）用于ES-SCLC一线治疗的上市许可申请自2023年3月提交EMA后仍在审评中。
2024-11-14Fosun Pharma disclosed that multiple innovative drugs entered pre-approval or key clinical stages in 2024, including: Fumetinib (2 indications) NDA accepted with priority review; Denosumab biosimilar HLX14 MAA accepted by EMA; Serplulimab combo for mCRC started Phase III in China; Serplulimab received positive CHMP opinion from EMA.复星医药披露2024年多款创新药进入上市前审批/关键临床阶段，包括：复迈替尼片2项适应症上市申请获受理并纳入优先审评；地舒单抗生物类似药HLX14上市许可申请获欧洲药品管理局受理；斯鲁利单抗联合贝伐珠单抗化疗用于转移性结直肠癌在中国启动III期临床；斯鲁利单抗获欧洲药品管理局人用医药产品委员会积极审评意见。
2024-12-03Subsidiary Henlius' Han Si Zhuang (serplulimab injection) new indication approved by NMPA for first-line treatment of non-squamous non-small cell lung cancer (nsNSCLC).子公司复宏汉霖的汉斯状（斯鲁利单抗注射液）新适应症获国家药监局批准，用于非鳞状非小细胞肺癌一线治疗。
2025-02-05EU Commission approved MAA for serplulimab (Hetronifly) + carboplatin + etoposide as first-line treatment for extensive-stage small cell lung cancer; first anti-PD-1 approved in EU for ES-SCLC.欧盟委员会批准斯鲁利单抗（Hetronifly）联合卡铂和依托泊苷用于广泛期小细胞肺癌一线治疗；成为欧盟首个获批用于ES-SCLC的抗PD-1单抗。
2025-04-25Subsidiary Henlius grants Alvogen Korea exclusive commercialization rights for serplulimab injection in South Korea for 5 cancer indications, with up to USD 14.5 million upfront and milestone payments and up to USD 97.5 million sales milestones.控股子公司复宏汉霖授予Alvogen Korea在韩国独家商业化斯鲁利单抗注射液的权利，涉及5个癌种，首付款及里程碑付款至多1450万美元，销售里程碑至多9750万美元。
2025-04-29Fosun Pharma's self-developed anti-PD-1 mAb serplulimab (Hetronifly) receives EU approval for first-line ES-SCLC; self-developed Foritinib (SAF-189) NDA accepted by NMPA; HLX22 gets FDA Orphan Drug Designation for gastric cancer.复星医药自主研发的斯鲁利单抗（Hetronifly）获欧盟批准用于ES-SCLC一线治疗；丁二酸复瑞替尼（Foritinib）上市申请获国家药监局受理；HLX22获FDA孤儿药资格认定用于胃癌。
2025-07-31Subsidiary Henlius completed first batch shipment of anti-PD-1 mAb H (Hanlizhuang, serplulimab) to India; first global approval for first-line ES-SCLC; approved in ~40 countries.子公司复宏汉霖完成抗PD-1单抗H药（汉斯状，斯鲁利单抗）首批面向印度市场的供货；该药是全球首个获批一线治疗广泛期小细胞肺癌的抗PD-1单抗，已在近40个国家和地区获批。
2025-10-28Fosun Pharma's PD-1 inhibitor Serplulimab (汉斯状) Phase III for gastric cancer neoadjuvant/adjuvant reached primary endpoint, supporting early NDA submission.复星医药PD-1抑制剂斯鲁利单抗（汉斯状）用于胃癌新辅助/辅助治疗的III期研究达主要终点，可支持提前申报上市。
2025-11-20Henlius' serplulimab injection (Han Si Zhuang) was included in China's breakthrough therapy designation for neoadjuvant/adjuvant chemotherapy in gastric cancer.复宏汉霖的斯鲁利单抗注射液（汉斯状®）用于胃癌新辅助/辅助化疗被纳入中国突破性治疗药物程序。
2025-12-12Subsidiary Henlius' sBLA for serplulimab injection (Han Si Zhuang) new indication (neoadjuvant + adjuvant for PD-L1+ resectable gastric cancer) accepted by NMPA with priority review.子公司复宏汉霖的斯鲁利单抗注射液（汉斯状）新增适应症（PD-L1阳性可手术切除胃癌的新辅助+辅助治疗）的补充申请获国家药监局受理并纳入优先审评。
2026-03-09Henlius' anti-PD-1 mAb HANSIZHUANG (serplulimab, European trade name Hetronifly) had multiple studies selected for 2026 ELCC, covering SCLC and NSCLC; approved in over 40 countries.复宏汉霖自主研发的创新型抗PD-1单抗H药汉斯状®（斯鲁利单抗，欧洲商品名Hetronifly®）多项研究入选2026年欧洲肺癌大会，覆盖小细胞肺癌和非小细胞肺癌；已在超40个国家获批上市。
2026-05-10Subsidiary Henlius received EC approval for two new indications of Serplulimab Injection (Hetronifly®): first-line ESCC (PD-L1 CPS≥5) and first-line nsNSCLC (EGFR/ALK/ROS1 negative); cumulative R&D investment ~3.691 billion yuan.控股子公司复宏汉霖斯鲁利单抗注射液（Hetronifly®）获欧盟委员会批准新增两项适应症：一线食管鳞状细胞癌（PD-L1 CPS≥5）和一线非鳞非小细胞肺癌（EGFR/ALK/ROS1阴性）；累计研发投入约36.91亿元。
2026-06-09Fosun Pharma's subsidiary Henlius received NMPA approval for a new indication of Serplulimab Injection (Han Si Zhuang): neoadjuvant and adjuvant therapy for resectable gastric cancer with PD-L1 CPS≥5, the world's first perioperative immunotherapy regimen replacing adjuvant chemotherapy.复星医药子公司复宏汉霖的斯鲁利单抗注射液（汉斯状）获国家药监局批准新适应症：联合奥沙利铂和替吉奥用于PD-L1 CPS≥5的可手术切除胃癌新辅助及术后单药辅助治疗，为全球首个胃癌围术期免疫单药替代化疗方案。
2026-06-25Fosun Pharma's subsidiary Henlius received European Commission approval for a new indication of Serplulimab Injection (Hetronifly): first-line treatment of unresectable locally advanced or metastatic squamous non-small cell lung cancer in combination with carboplatin and nab-paclitaxel.复星医药子公司复宏汉霖的斯鲁利单抗注射液（Hetronifly）获欧盟委员会批准新适应症：联合卡铂和白蛋白紫杉醇用于不可手术切除的局部晚期或转移性鳞状非小细胞肺癌一线治疗。
2026-08-03Henlius will present at WCLC 2026 (Sept 12-15, Seoul) Phase I data for PD-L1 ADC HLX43 in thymic squamous cell carcinoma and 7 studies for anti-PD-1 serplulimab (H药汉斯状/Hetronifly) in lung cancers.复宏汉霖将在2026年世界肺癌大会（9月12-15日，首尔）公布PD-L1 ADC HLX43在胸腺鳞癌的I期数据，以及抗PD-1单抗斯鲁利单抗（H药汉斯状/Hetronifly）在肺癌领域的7项研究数据。
Drug approvals & regulatory milestones药品获批与监管里程碑
24 · 2024-01-02 → 2026-03-24
▾
Key drug approvals, NDA acceptances, and regulatory milestones for innovative and generic drugs.创新药和仿制药的关键获批、上市申请受理及监管里程碑。
2024-01-02Three new drugs (Beiwen, Peijin, Yixintan) included in the 2024 National Reimbursement Drug List.三款新药（倍稳、珮金、一心坦）纳入新版国家医保药品目录。
2024-01-10Subsidiary Fosun Medical Tech's exclusive agent Profhilo (injectable hyaluronic acid solution) NDA accepted by NMPA in Nov 2023 for moderate-to-severe frown lines.控股子公司复锐医疗独家代理的注射填充产品Profhilo（注射用透明质酸钠溶液）注册申请于2023年11月获国家药监局受理，用于改善中重度皱眉纹。
2024-04-29Fosun Pharma's self-developed denosumab biosimilar HLX14 (recombinant anti-RANKL mAb) for postmenopausal osteoporosis met primary endpoint in international multi-center Phase III study.复星医药自主研发的地舒单抗生物类似药HLX14用于绝经后妇女骨质疏松症的国际多中心III期研究达到主要终点。
2024-06-21Fosun Pharma's subsidiary Jiangsu Wanbang and Novelstar Pharmaceuticals' Guanfacine Hydrochloride Extended-Release Tablets (1-4mg) for ADHD received FDA approval.复星医药子公司江苏万邦与Novelstar合作开发的盐酸胍法辛缓释片（1-4mg）用于ADHD获美国FDA批准。
2024-07-15Fosun Pharma's subsidiary Guilin Pharma's Molnupiravir capsules 200mg received WHO prequalification (WHO-PQ), the first capsule product from Guilin Pharma to achieve this.复星医药旗下桂林南药的莫纳皮拉韦胶囊200mg通过世界卫生组织药品预认证（WHO-PQ），为该公司首个获此认证的胶囊剂型。
2024-08-02Fosun Medical's subsidiary Futuodazhi's disposable pulmonary nodule localization marker approved for marketing in China.复星医疗旗下复拓知达的一次性使用肺结节定位标记物在中国获批上市。
2024-12-05Subsidiary Shenyang Hongqi's Prine (pretomanid tablet) approved by NMPA for highly drug-resistant pulmonary tuberculosis.子公司沈阳红旗的普瑞尼（普托马尼片）获国家药监局批准，用于高度耐药肺结核。
2024-12-17Subsidiary Guilin Nanyao's second-generation injectable artesunate (Argesun) 180mg and 120mg received WHO prequalification.子公司桂林南药的第二代注射用青蒿琥酯（Argesun）180mg和120mg规格获世界卫生组织预认证。
2025-01-09Subsidiary Jinzhou Aohong Pharma's FCN-437c (citrate fovestinib capsule, novel CDK4/6 inhibitor) NDA accepted by NMPA for HR+/HER2- advanced breast cancer; cumulative R&D investment ~574 million yuan.控股子公司锦州奥鸿药业的枸橼酸伏维西利胶囊（FCN-437c，新型CDK4/6抑制剂）药品注册申请获国家药监局受理，用于HR+/HER2-晚期乳腺癌；累计研发投入约5.74亿元。
2025-02-10FDA approved IND for HLX99, a novel small-molecule conjugate drug for amyotrophic lateral sclerosis; cumulative R&D investment ~RMB 13 million.美国FDA批准HLX99（创新型小分子偶联化学药物）用于肌萎缩侧索硬化的临床试验申请；累计研发投入约1300万元。
2025-02-26NMPA approved marketing of tenapanor (Wantile), a first-in-class NHE3 inhibitor licensed from Ardelyx, for controlling serum phosphorus in dialysis patients with CKD who are inadequately controlled on phosphate binders.国家药监局批准盐酸替那帕诺片（万缇乐）上市，用于对磷结合剂疗效不充分或不耐受的慢性肾脏病透析患者控制血清磷水平；该药为从Ardelyx许可引入的First-in-class NHE3抑制剂。
2025-03-06Subsidiary Fosun Wanbang's NDA for Foritinib (SAF-189, a Class 1 chemical new drug for ALK+/ROS1+ NSCLC) accepted by NMPA; cumulative R&D investment in China approx. RMB 439 million.控股子公司复星万邦的丁二酸复瑞替尼胶囊（SAF-189，化药1类，用于ALK+/ROS1+非小细胞肺癌）药品注册申请获国家药监局受理，中国境内累计研发投入约4.39亿元。
2025-05-29NMPA approved the marketing of Fuvoxeciclib capsules (Futuoning, FCN-437c), a CDK4/6 inhibitor, for HR+/HER2- advanced breast cancer; cumulative R&D ~RMB 601 million.国家药监局批准枸橼酸伏维西利胶囊（复妥宁，FCN-437c）上市，用于HR+/HER2-晚期乳腺癌；累计研发投入约6.01亿元。
2025-07-01Subsidiary Futuozhida's lung nodule marker placement positioning device received NMPA approval; uses AR glasses for 3D-guided VATS surgery without preoperative CT puncture.子公司复拓知达的肺结节标记物放置定位设备获国家药监局批准，采用AR眼镜3D引导胸腔镜手术，无需术前CT穿刺。
2025-08-28Fosun Pharma's self-developed COVID-19 and Influenza A/B nucleic acid test kit received NMPA registration approval for market launch.复星医药自主研发的新型冠状病毒及甲型/乙型流感病毒核酸检测试剂盒获国家药监局注册批准上市。
2025-09-08Fosun Pharma subsidiary Fosun Wanbang received NMPA approval for Phase III trial of SAF-189 (furetinib disuccinate capsules, Class 1 chemical drug) for adjuvant treatment of ALK-positive or ROS1-positive stage IB-IIIA NSCLC after radical resection; cumulative R&D investment approx. RMB 453 million.复星医药子公司复星万邦获国家药监局批准开展丁二酸复瑞替尼胶囊（SAF-189，化药1类）用于ALK阳性或ROS1阳性IB-IIIA期非小细胞肺癌术后辅助治疗的III期临床试验；累计研发投入约4.53亿元。
2025-10-14Fosun Wanbang (subsidiary) withdrew the registration application for Furuitinib (丁二酸复瑞替尼胶囊, SAF-189) for ALK+/ROS1+ NSCLC; will refile after improving data.复星万邦撤回丁二酸复瑞替尼胶囊（SAF-189）用于ALK+/ROS1+非小细胞肺癌的注册申请，将完善资料后重新提交。
2025-10-28Fosun Pharma's innovative drug revenue exceeded RMB 6.7B in 9M 2025, up 18.09% YoY; CDK4/6 inhibitor Futuoning (伏维西利) approved for new breast cancer indication in China.复星医药2025年前三季度创新药品收入超67亿元，同比增长18.09%；CDK4/6抑制剂复妥宁（伏维西利）在中国获批新乳腺癌适应症。
2025-11-21At Q3 results briefing, Fosun Pharma set 2025-2027 CAGR target of 20% for innovative drug revenue; disclosed that CDK4/6 inhibitor Futuoning (vobesilib citrate) received a new indication approval in China for breast cancer.三季度业绩说明会上，复星医药设定2025-2027年创新药品收入年复合增长率20%的目标；披露CDK4/6抑制剂复妥宁（枸橼酸伏维西利胶囊）在中国获批乳腺癌新适应症。
2025-12-07Multiple products newly included in 2025 National Reimbursement Drug List (e.g., lumefantrine tablets) and first Commercial Health Insurance Innovative Drug List (e.g., axicabtagene ciloleucel injection); positive impact on future performance expected.多款产品新纳入2025年国家医保目录（如芦沃美替尼片）和首版商保创新药目录（如阿基仑赛注射液）；预计对后续业绩产生积极影响。
2026-01-08Fosun Pharma's subsidiary Fosun Wanbang resubmitted a drug registration application for Furutinib (SAF-189, class 1 chemical) for ALK-positive locally advanced or metastatic NSCLC, which was accepted by the NMPA; cumulative R&D investment about 480 million yuan.复星医药控股子公司复星万邦就丁二酸复瑞替尼胶囊（SAF-189，化药1类）再次递交的药品注册申请获国家药监局受理，适应症为ALK阳性局部晚期或转移性非小细胞肺癌；累计研发投入约4.80亿元。
2026-03-10Licensed-in innovative drug Tenapanor hydrochloride tablets (brand name Wan Ti Le), the world's first and only approved phosphate absorption inhibitor, had its first prescription in China for hyperphosphatemia in CKD dialysis patients.许可引进的创新药盐酸替那帕诺片（商品名：万缇乐），全球首个且唯一获批的磷吸收抑制剂，在中国开出首张处方，用于慢性肾脏病透析患者高磷血症治疗。
2026-03-24In 2025, 7 innovative drugs with 16 indications were approved for marketing domestically and overseas; 6 innovative drug NDA submissions were accepted; nearly 40 innovative drug clinical trials were approved by China, US, and EU regulators.2025年，7个创新药品共16项适应症于境内外获批上市，6个创新药品种上市申请获受理，近40项创新药临床试验获中美欧批准。
2026-03-24Fosun Pharma's nuclear medicine project SRT-007 initiated Phase I clinical trial; autologous dual-target CAR-T product FKC289 IND application accepted by NMPA.复星医药核药项目SRT-007启动I期临床试验；自体双靶点CAR-T产品FKC289临床试验申请获国家药监局受理。
Guarantees for subsidiaries为子公司提供担保
13 · 2024-01-05 → 2026-03-06
▾
Recurring provision of loan guarantees and credit support to various subsidiaries.向多家子公司反复提供贷款担保和信用支持。
2024-01-05Company to provide guarantee for subsidiary Fosun Industrial's loan up to RMB 500M from MUFG Bank, and for subsidiary Fosun Industrial's loan up to USD 100M from AIIB.公司拟为控股子公司复星医药产业向三菱银行申请的不超过5亿元融资函提供担保，并为复星实业向AIIB申请的不超过1亿美元贷款提供担保。
2024-02-07Fosun Pharma provided a maximum joint liability guarantee of up to RMB 200 million for its subsidiary Fosun Pharma Industrial's credit line with Shengjing Bank.复星医药为其控股子公司复星医药产业向盛京银行申请的授信额度提供最高额2亿元连带责任保证担保。
2024-02-19Fosun Pharma provided a joint liability guarantee of RMB 100 million for its subsidiary Fosun Pharma Industrial's working capital loan from Shanghai Rural Commercial Bank.复星医药为其控股子公司复星医药产业向上海农商行申请的1亿元流动资金贷款提供连带责任保证担保。
2024-04-10Fosun Pharma disclosed total external guarantees of approximately 26.619 billion yuan as of April 9, 2024, accounting for 58.27% of net assets attributable to shareholders.复星医药披露截至2024年4月9日对外担保金额约266.19亿元，占归母净资产的58.27%。
2024-10-17Fosun Pharma provided guarantees totaling up to 360 million yuan for subsidiary loans: 350 million yuan fixed-asset loan for Fosun Yalifeng from China Exim Bank, and 10 million yuan credit line for Fosun Pharma Industrial from Bank of Nanjing.复星医药为子公司贷款提供合计不超过3.6亿元的担保：为复星雅立峰向进出口银行申请3.5亿元固定资产贷款，为复星医药产业向南京银行申请1000万元授信额度提供担保。
2024-12-19Fosun Pharma provided guarantees: up to USD 120 million for subsidiary Fosun Industrial, RMB 10 million for Hanlin Pharma, RMB 3 million for Nanchang Jianjia.复星医药提供担保：为复星实业提供不超过1.2亿美元担保，为汉霖制药提供1000万元担保，为南昌健嘉提供300万元担保。
2025-04-03Fosun Pharma provides guarantees totaling approx. RMB 2.457 billion to subsidiaries including Fosun Health, Fosun Pharma Industry, etc., accounting for 51.99% of net assets.复星医药为复星健康、复星医药产业等控股子公司提供合计约24.57亿元的担保，占净资产的51.99%。
2025-05-13Fosun Pharma provided a joint liability guarantee of up to RMB 700 million for subsidiary Fosun Pharma Industrial's credit line with OCBC Bank.复星医药为控股子公司复星医药产业向华侨银行申请的信贷额度提供最高额7亿元连带责任保证担保。
2025-06-12Fosun Pharma provided guarantees for subsidiaries totaling over RMB 16.5 billion, including new guarantees and adjustments to existing ones.复星医药为多家控股子公司新增及调整担保，总额超过165亿元。
2025-07-09Company provided guarantees totaling RMB 650M for subsidiaries Fosun Pharma Industrial (RMB 500M) and Hanlin Pharma (RMB 150M) for bank financing.公司为子公司复星医药产业（5亿元）和汉霖制药（1.5亿元）提供合计6.5亿元的融资担保。
2025-08-09Fosun Pharma provided guarantees totaling RMB 141.5 million to six subsidiaries (Nantong Jianjia, Shantou Jianjia, Xi'an Jianjia, Yangzhou Jianjia, Fosun Antigen, and Sinopharm Med-Tech) for daily operations and financing.复星医药为六家控股子公司（南通健嘉、汕头健嘉、西安健嘉、扬州健嘉、复星安特金、美中互利）提供合计1.415亿元担保，支持日常经营及融资。
2025-10-15Fosun Pharma provided guarantees totaling ~RMB 1.344 billion for 9 subsidiaries, bringing total guarantees to ~RMB 23.377 billion (49.46% of 2024 net assets).复星医药为9家控股子公司提供约13.44亿元担保，累计对外担保余额约233.77亿元（占2024年末净资产的49.46%）。
2026-03-06Fosun Pharma provided new guarantees totaling RMB 196 million to five subsidiaries including Hanlin Shenzhen, Meizhong Huli (Beijing), Shanghai Jianjia, Fuzhou Jianjia, and Nanchang Jianjia.复星医药为汉霖深圳、美中互利（北京）、上海健嘉、福州健嘉及南昌健嘉五家控股子公司新增担保总额1.96亿元。
Insilico Medicine collaboration英矽智能合作
3 · 2024-01-09 → 2024-07-05
▾
Equity holding and AI-driven drug discovery collaboration with Insilico Medicine.持有英矽智能股权并进行AI驱动的药物发现合作。
2024-01-09Company holds 524,051 C+ round convertible redeemable preferred shares of Insilico Medicine, about 2.54% of total shares as of June 20, 2023.公司持有英硅智能524,051股C+轮可转换可赎回优先股，约占其截至2023年6月20日股份总数的2.54%。
2024-06-05Fosun Pharma disclosed partnership with AI drug R&D firm Insilico Medicine to co-develop small-molecule innovative drugs, and exploring AI large models for drug discovery.复星医药披露与AI药物研发企业英矽智能合作，共同开发小分子创新药，并探索AI大模型在药物发现中的应用。
2024-07-05Insilico Medicine delivered a second preclinical candidate (PCC) to Fosun Pharma under their collaboration, targeting a synthetic lethality strategy for solid tumors; IND filing expected in Q4 2024.英矽智能向复星医药交付第二款临床前候选化合物（PCC），靶向合成致死策略用于实体瘤，预计2024年第四季度提交IND申请。
Subsidiaries & new entities子公司与新实体
15 · 2024-01-09 → 2026-04-22
▾
Establishment of new subsidiaries, restructuring of existing ones, and related corporate actions.新子公司的设立、现有子公司的重组及相关公司行为。
2024-01-09Subsidiary Fosun Kate recognized as 2023 Pudong New Area Enterprise R&D Institution.控股子公司复星凯特被认定为2023年度浦东新区企业研发机构。
2024-06-12Fosun Pharma established a wholly-owned subsidiary, Fosun Yaohong (Tibet) Pharmaceutical Technology Co., Ltd., with registered capital of RMB 30 million, covering drug wholesale and health services.复星医药成立全资子公司复星曜泓（西藏）医药科技有限公司，注册资本3000万元，经营范围包括药品批发和健康服务。
2024-07-30Fosun Pharma added a new implementation entity (Fosun Pharma Shenzhen) for its 2022 private placement fund projects, approved by the board and supervisor, with a new special account to be opened.复星医药新增2022年非公开发行募投项目实施主体复星医药（深圳），经董事会和监事会审议通过，将新设募集资金专户。
2024-08-13Fosun Pharma (Xuzhou) and Fosun Pharma (Shenzhen) signed new tripartite supervision agreements for raised funds with CICC and commercial banks.复星医药（徐州）和复星医药（深圳）与中金公司及商业银行签订了新的募集资金专户存储三方监管协议。
2024-09-14Fosun Pharma's Greater Bay Area office in Shenzhen was officially inaugurated to accelerate innovation and international expansion.复星医药大湾区办公室在深圳正式启用，以加快大湾区及国际化创新发展布局。
2024-10-23Fosun Pharma established a new subsidiary, Jiangsu Fosun Jinnuo Pharmaceutical Co., Ltd., with registered capital of 30 million yuan, for drug production and R&D.复星医药成立新子公司江苏复星金诺药业有限公司，注册资本3000万元，从事药品生产和研发。
2024-11-15Fosun Pharma indirectly wholly-owned subsidiary Beijing Zhixingda Medical Technology Co., Ltd. was established, with registered capital of RMB 960,000, focusing on AI software development and design services.复星医药间接全资持股的北京知星达医疗科技有限公司成立，注册资本96万元，专注于人工智能基础软件开发及设计服务。
2024-12-06Fosun Pharma indirectly wholly-owned subsidiary Shanghai Xingtao Biomedical established with registered capital of RMB 10,000.复星医药间接全资子公司上海星韬生物医药成立，注册资本1万元。
2025-02-18Established Fosun Pharma (Nanning) Co., Ltd. with registered capital of RMB 100 million, held by Fosun Pharma Industrial, Zhongheng Yixin, and Nanning Chan Tou, engaged in drug wholesale, retail, import/export.成立复星医药（南宁）有限责任公司，注册资本1亿元，由复星医药产业、中恒怡鑫、南宁产投持股，经营药品批发、零售、进出口等。
2025-03-26Establishes Xingmaitaike Medical Technology (Beijing) Co., Ltd., indirectly wholly owned by Fosun Pharma, with registered capital of RMB 3 million, for medical device sales and health consulting.间接全资持股成立星迈泰科医疗科技（北京）有限公司，注册资本300万元，从事医疗器械销售及健康咨询服务。
2025-07-17New subsidiary Guangdong Xingchan Health Technology Co., Ltd. established with registered capital of RMB 10M, wholly owned by Fosun Health Technology (Group), focusing on remote health management and cloud computing.新设子公司广东星禅健康科技有限公司成立，注册资本1000万元，由复星健康科技（集团）有限公司全资持股，专注于远程健康管理和云计算技术服务。
2025-08-06Fosun Pharma established a wholly-owned subsidiary, Fosun Pharma Industrial Development (Chengdu) Co., Ltd., with a registered capital of RMB 10 million, to strengthen its western China pharmaceutical industry layout.复星医药在成都设立全资子公司复星医药产业发展（成都）有限公司，注册资本1000万元，强化西部医药产业布局。
2025-09-03Chengdu Fosun Medical Equipment Co., Ltd. was established with registered capital of RMB 2 million, wholly owned by Beijing Jingyi Information Technology Co., Ltd.成都复星医疗器械有限公司成立，注册资本200万元人民币，由北京惊医信息科技有限公司全资持股。
2026-04-07Fosun Pharma indirectly wholly owned a new subsidiary, Zhuhai Xingtao Pharmaceutical Technology, with registered capital of 10 million yuan, focusing on medical research and development.复星医药间接全资持股新设珠海星韬医药科技有限公司，注册资本1000万元，经营范围包括医学研究和试验发展。
2026-04-22Fosun Pharma completed internal restructuring of its stake in Sisram Medical (01696.HK): indirect wholly owned subsidiaries Nengyue and Meizhong Huli transferred their combined 71.42% stake to another indirect wholly owned subsidiary FPI, with no change in overall ownership.复星医药完成对复锐医疗科技（01696.HK）股权的内部重组：间接全资附属公司能悦与美中互利将其合计71.42%股份转让给另一间接全资附属公司FPI，整体持股比例不变。
Generic drug approvals & filings仿制药获批与申报
53 · 2024-01-10 → 2026-08-07
▾
A steady stream of NMPA approvals and registration acceptances for generic drugs from various subsidiaries.来自不同子公司的仿制药获得NMPA批准和注册受理的稳定流程。
2024-01-10Subsidiary Jinzhou Aohong Pharma's self-developed Famotidine Injection NDA accepted by NMPA for upper GI bleeding.控股子公司锦州奥鸿药业自主研发的法莫替丁注射液药品注册申请获国家药监局受理，用于上消化道出血。
2024-02-20Fosun Pharma's subsidiary Chongqing Yaoyou Pharmaceutical's self-developed Potassium Chloride Extended-Release Tablets (small molecule chemical drug) received drug registration application acceptance from the NMPA for hypokalemia prevention and treatment.复星医药控股子公司重庆药友制药自主研发的氯化钾缓释片（小分子化学药物）获国家药监局药品注册申请受理，拟用于预防和治疗低钾血症。
2024-03-13Subsidiaries Fosun Pharma Industrial and Jinzhou Aohong Pharmaceutical received NMPA marketing approval for Aripiprazole Oral Solution for schizophrenia in adolescents (13-17 years) and adults; cumulative R&D investment ~RMB 6.12 million.控股子公司复星医药产业及锦州奥鸿药业获国家药监局批准阿立哌唑口服溶液用于13-17岁青少年和成人精神分裂症上市；累计研发投入约612万元。
2024-04-08Fosun Pharma subsidiary's self-developed deferasirox granules and tablets (for chronic iron overload) received NMPA drug registration application acceptance.复星医药子公司自主研发的地拉罗司颗粒和片剂（用于慢性铁过载）获国家药监局药品注册申请受理。
2024-04-17Fosun Pharma subsidiary Guilin Nanyang's foscarnet sodium injection (for CMV retinitis in AIDS patients and acyclovir-resistant HSV) received NMPA drug registration application acceptance.复星医药子公司桂林南药的膦甲酸钠注射液（用于AIDS患者巨细胞病毒性视网膜炎等）获国家药监局药品注册申请受理。
2024-04-24Fosun Pharma subsidiary Shenyang Hongqi's self-developed cycloserine capsules (for drug-resistant tuberculosis) received NMPA marketing approval.复星医药子公司沈阳红旗制药自主研发的环丝氨酸胶囊（用于耐药结核）获国家药监局上市批准。
2024-05-09Subsidiary Chongqing Yaoyou received NMPA approval for its self-developed Aripiprazole Orally Disintegrating Tablet for schizophrenia.控股子公司重庆药友自主研发的阿立哌唑口崩片获国家药监局批准，用于治疗精神分裂症。
2024-05-27Subsidiaries Jinzhou Aohong and Liaoning Children's Pharma received NMPA approval for self-developed Desloratadine Oral Solution for chronic idiopathic urticaria and allergic rhinitis.控股子公司锦州奥鸿药业和辽宁儿童制药自主研发的地氯雷他定口服溶液获国家药监局批准，用于缓解慢性特发性荨麻疹及过敏性鼻炎。
2024-05-27Subsidiary Jinzhou Aohong's self-developed Norepinephrine Bitartrate Injection marketing application was accepted by NMPA for raising blood pressure in severe acute hypotension.控股子公司锦州奥鸿药业自主研发的重酒石酸去甲肾上腺素注射液的药品注册申请获国家药监局受理。
2024-06-27Fosun Pharma's subsidiary Chongqing Yaoyou's self-developed Nicorandil Injection for unstable angina received NMPA approval; cumulative R&D investment ~RMB 4.46 million.复星医药子公司重庆药友自主研发的注射用尼可地尔用于不稳定型心绞痛获国家药监局批准；累计研发投入约446万元。
2024-07-08Fosun Pharma's subsidiary Hunan Dongting Pharmaceutical received NMPA approval for the marketing application of Levetiracetam Extended-Release Tablets as adjunctive therapy for partial-onset seizures in patients aged 12 and above.复星医药控股子公司湖南洞庭药业的左乙拉西坦缓释片获国家药监局批准上市，用于12岁及以上癫痫患者部分性发作的加用治疗。
2024-07-19Fosun Pharma's subsidiary Chongqing Kailin Pharmaceutical's Sodium Thiosulfate Injection new drug application was accepted by NMPA for cyanide poisoning and arsenic, mercury, lead, bismuth, iodine poisoning.复星医药控股子公司重庆凯林制药的硫代硫酸钠注射液药品注册申请获国家药监局受理，用于氰化物及砷、汞、铅、铋、碘等中毒。
2024-07-22Fosun Pharma's subsidiary Chongqing Yaoyou Pharmaceutical received NMPA acceptance of registration applications for Sodium Nitroprusside Injection and Flurbiprofen Axetil Injection.复星医药控股子公司重庆药友制药的硝普钠注射液和氟比洛芬酯注射液药品注册申请获国家药监局受理。
2024-08-12Fosun Pharma had 27 generic drugs pass consistency evaluation in H1 2024, cumulative over 110 varieties passed, with about 30 selected in national procurement.2024年上半年复星医药有27个仿制药通过一致性评价，累计超110个品种过评，约30个品种在国家集采中中选。
2024-09-13Subsidiary Jiangsu Wanbang's Empagliflozin Metformin Extended-Release Tablets (for type 2 diabetes) received NMPA drug registration application acceptance.控股子公司江苏万邦的恩格列净二甲双胍缓释片（用于2型糖尿病）获国家药监局药品注册申请受理。
2024-09-27Subsidiary Jinzhou Aohong's SBK10 oral solution (for mild-to-moderate acute ischemic stroke) received NMPA drug registration application acceptance.控股子公司锦州奥鸿药业的SBK10口服溶液（用于轻、中度急性缺血性脑卒中）获国家药监局药品注册申请受理。
2024-09-29Subsidiary Jisimei (Wuhan) obtained NMPA marketing approval for Oxaliplatin Injection, used for metastatic colorectal cancer, adjuvant therapy for stage III colon cancer, and advanced hepatocellular carcinoma.控股子公司吉斯美（武汉）制药的奥沙利铂注射液获国家药监局上市批准，用于转移性结直肠癌、III期结肠癌辅助治疗及晚期肝细胞癌等。
2024-10-14Fosun Pharma's subsidiary Shanghai Zhaohui Pharmaceutical received NMPA acceptance of the registration application for its self-developed Dobutamine Hydrochloride Injection, for acute circulatory insufficiency.复星医药控股子公司上海朝晖药业的盐酸多巴酚丁胺注射液的药品注册申请获国家药监局受理，用于急性循环功能不全。
2024-10-17Fosun Pharma's subsidiary Fosun Pharma (Xuzhou) received NMPA acceptance of the registration application for its self-developed Venlafaxine Hydrochloride Extended-Release Tablets, for depression and anxiety disorders.复星医药控股子公司复星医药（徐州）的盐酸文拉法辛缓释片的药品注册申请获国家药监局受理，用于治疗抑郁症及广泛性焦虑障碍。
2024-10-30Fosun Pharma's subsidiary Chongqing Yaoyou Pharmaceutical received NMPA approval for its self-developed injection of Roxatidine Acetate Hydrochloride for upper gastrointestinal bleeding.复星医药控股子公司重庆药友制药的注射用盐酸罗沙替丁醋酸酯获国家药监局批准上市，用于上消化道出血治疗。
2024-11-04Fosun Pharma's subsidiaries Chongqing Yaoyou and Jisimei (Wuhan) received NMPA acceptance for drug registration applications for Levofloxacin Injection and Cytarabine Injection, with cumulative R&D investment of approximately RMB 1.33 million and RMB 2.57 million respectively.复星医药控股子公司重庆药友制药和吉斯美（武汉）制药的左氧氟沙星注射液和阿糖胞苷注射液的药品注册申请获国家药监局受理，累计研发投入分别约为133万元和257万元。
2024-12-03Subsidiary Henan Wanbang Fulin received NMPA acceptance of registration application for Taohong Siwu Granules (TCM 3.1 class new drug) for blood deficiency and blood stasis syndrome.子公司河北万邦复临的桃红四物颗粒（中药3.1类新药）获国家药监局注册申请受理，用于血虚血瘀证。
2024-12-06Fosun Pharma ranked first in November with 9 drug varieties passing consistency evaluation (including 5 via supplementary application).复星医药11月有9个品种通过一致性评价（含5个补充申请），排名第一。
2025-01-02Subsidiary Jisimei (Wuhan) Pharmaceutical's raltitrexed for injection NDA accepted by NMPA for advanced colorectal cancer; cumulative R&D investment ~2.96 million yuan.控股子公司吉斯美（武汉）制药的注射用雷替曲塞药品注册申请获国家药监局受理，用于晚期结直肠癌；累计研发投入约296万元。
2025-01-20Subsidiary Jinzhou Aohong Pharma's metaraminol bitartrate injection approved by NMPA for hypotension; cumulative R&D investment ~8.56 million yuan.控股子公司锦州奥鸿药业的重酒石酸间羟胺注射液获国家药监局批准上市，用于低血压；累计研发投入约856万元。
2025-01-20Subsidiary Hunan Dongting Pharma's oxazepam tablets approved by NMPA for anxiety and related conditions; cumulative R&D investment ~9.77 million yuan.控股子公司湖南洞庭药业的奥沙西泮片获国家药监局批准上市，用于焦虑等症状；累计研发投入约977万元。
2025-01-24Subsidiary Fosun Pharma (Xuzhou)'s levalbuterol hydrochloride nebulization solution NDA accepted by NMPA for bronchospasm; cumulative R&D investment ~4.54 million yuan.控股子公司复星医药（徐州）的盐酸左沙丁胺醇雾化吸入溶液药品注册申请获国家药监局受理，用于支气管痉挛；累计研发投入约454万元。
2025-02-10NMPA accepted registration applications for polymyxin B sulfate for injection (resistant Gram-negative infections) and labetalol hydrochloride injection (severe hypertension).国家药监局受理注射用硫酸多黏菌素B（耐药革兰氏阴性菌感染）和盐酸拉贝洛尔注射液（严重高血压）的药品注册上市申请。
2025-02-26NMPA approved marketing of compound sodium picosulfate granules (class 3 chemical drug) for bowel cleansing before colonoscopy/X-ray/surgery.国家药监局批准复方匹可硫酸钠颗粒（化药3类）上市，用于结肠镜检查、X射线检查及外科手术前的肠道清洁准备。
2025-02-26NMPA accepted registration application for bromhexine hydrochloride injection, a self-developed chemical drug for expectoration in tuberculosis, pneumoconiosis, and post-surgery.国家药监局受理盐酸溴己新注射液（自主研发化学药品）的药品注册申请，用于肺结核、尘肺病及手术后祛痰。
2025-07-11Subsidiary Shanghai Zhaohui Pharmaceutical's drug registration application for compound polyethylene glycol electrolyte powder (II) accepted by NMPA; cumulative R&D ~RMB 4.74M; 2024 China sales ~RMB 307M.子公司上海朝晖药业有限公司的复方聚乙二醇电解质散（Ⅱ）药品注册申请获国家药监局受理，累计研发投入约474万元，2024年中国境内销售额约3.07亿元。
2025-08-12Fosun Pharma's subsidiary Jisimei (Wuhan) received NMPA acceptance of its drug registration application for Nedaplatin for injection, a self-developed chemotherapy for multiple cancers.复星医药子公司吉斯美（武汉）注射用奈达铂的药品注册申请获国家药监局受理，该药为自主研发的化疗药，用于多种癌症。
2025-08-26Fosun Pharma's subsidiary Jisimei (Wuhan) received NMPA acceptance of its drug registration application for Vincristine Sulfate Injection, a chemotherapy drug.复星医药子公司吉斯美（武汉）硫酸长春新碱注射液的药品注册申请获国家药监局受理。
2025-10-24Fosun Pharma's subsidiary obtained NMPA approval for deferasirox tablets and granules for chronic iron overload in beta-thalassemia patients (age >2).复星医药子公司地拉罗司片及颗粒获国家药监局批准，用于β-地中海贫血患者慢性铁过载（年龄>2岁）。
2025-11-18Subsidiary Shanghai Zhaohui Pharma's drug registration application for compound polyethylene glycol (3350) electrolyte powder (for chronic constipation) was accepted by China NMPA.控股子公司上海朝晖药业的复方聚乙二醇（3350）电解质散（用于慢性便秘）药品注册申请获国家药监局受理。
2025-12-02Subsidiary Suzhou Erye's ANDA for heparin sodium injection was accepted by NMPA; cumulative R&D investment ~CNY 8.61M.子公司苏州二叶的肝素钠注射液药品注册申请获国家药监局受理；累计研发投入约861万元。
2025-12-10Subsidiary Guilin Nanyue received NMPA approval for foscarnet sodium injection for CMV retinitis in AIDS patients and acyclovir-resistant HSV mucocutaneous infections in immunocompromised patients.子公司桂林南药的膦甲酸钠注射液获国家药监局批准，用于艾滋病患者巨细胞病毒性视网膜炎和免疫功能损害患者耐阿昔洛韦单纯疱疹病毒性皮肤粘膜感染。
2026-01-14Fosun Pharma's subsidiary Suzhou Erye's drug registration application for erythromycin lactobionate for injection was accepted by the NMPA; cumulative R&D investment about 6.33 million yuan.复星医药控股子公司苏州二叶制药有限公司就注射用乳糖酸红霉素的药品注册申请获国家药监局受理；累计研发投入约633万元。
2026-01-22Fosun Pharma's subsidiary Jinzhou Aohong obtained NMPA approval for its self-developed norepinephrine bitartrate injection (4ml:8mg) for acute hypotension and cardiac arrest; cumulative R&D investment about 8.74 million yuan.复星医药控股子公司锦州奥鸿药业有限责任公司自主研发的重酒石酸去甲肾上腺素注射液（4ml:8mg）获国家药监局批准，用于急性低血压和心跳骤停；累计研发投入约874万元。
2026-03-20Subsidiary Chongqing Kailin Pharmaceutical obtained NMPA drug registration approval for sodium thiosulfate injection (4ml:1g) for cyanide and heavy metal poisoning; cumulative R&D investment ~RMB 1.87 million as of Feb 2026.控股子公司重庆凯林制药有限公司硫代硫酸钠注射液（4ml:1g）获国家药监局药品注册批准，用于氰化物及重金属中毒；截至2026年2月累计研发投入约187万元。
2026-04-10Subsidiary Chongqing Yaoyou Pharmaceutical received NMPA approval for flurbiprofen axetil injection for postoperative and cancer pain; cumulative R&D investment ~34 million yuan; 2025 China market sales ~1.158 billion yuan.子公司重庆药友制药的氟比洛芬酯注射液获国家药监局批准，用于术后及癌症镇痛；累计研发投入约0.34亿元；2025年中国境内销售额约11.58亿元。
2026-04-30Subsidiary Chongqing Yaoyou Pharmaceutical received NMPA approval for sodium nitroprusside injection for hypertensive emergencies and acute heart failure; cumulative R&D investment ~3.21 million yuan.子公司重庆药友制药的硝普钠注射液获国家药监局批准，用于高血压急症及急性心力衰竭；累计研发投入约321万元。
2026-05-06Subsidiary Chongqing Yaoyou Pharmaceutical received NMPA approval for its self-developed chemical drug Sodium Nitroprusside Injection.控股子公司重庆药友制药自主研发的化学药品硝普钠注射液获国家药监局批准。
2026-05-06Subsidiary Shenyang Hongqi Pharmaceutical received NMPA supplementary approval for Isoniazid Tablets passing generic consistency evaluation.控股子公司沈阳红旗制药异烟肼片通过仿制药一致性评价，获国家药监局补充批件。
2026-05-08Subsidiary Fosun Pharma (Xuzhou) received NMPA approval for self-developed chemical drug Venlafaxine Hydrochloride Extended-Release Tablets for depression and generalized anxiety disorder; cumulative R&D investment ~7.68 million yuan.控股子公司复星医药（徐州）自主研发的盐酸文拉法辛缓释片获国家药监局批准，用于抑郁症及广泛性焦虑障碍；累计研发投入约768万元。
2026-05-13Subsidiary Hebei Wanbang Fulin Pharmaceutical received NMPA acceptance for registration application of Taohong Siwu Decoction Granules (TCM 3.1 class new drug); cumulative R&D investment ~6.96 million yuan.控股子公司河北万邦复临药业桃红四物汤颗粒（中药3.1类新药）药品注册申请获国家药监局受理；累计研发投入约696万元。
2026-05-21Subsidiary Chongqing Yaoyou Pharmaceutical received NMPA approval for self-developed Levofloxacin Injection for 11 types of infections; cumulative R&D investment ~1.94 million yuan.控股子公司重庆药友制药自主研发的左氧氟沙星注射液获国家药监局批准，用于11种感染；累计研发投入约194万元。
2026-05-26Subsidiary Guilin Pharmaceutical received NMPA approval for Maribavir Tablets 0.2g (first generic in China) for post-transplant CMV infection refractory to prior therapy.成员企业桂林南药马立巴韦片0.2g获国家药监局批准上市（国内首家仿制药），用于移植后难治性巨细胞病毒感染。
2026-06-29Fosun Pharma's subsidiary Hebei Wanbang Fulin received NMPA approval for its traditional Chinese medicine granule 'Shaoyao Gancao Tang Keli' (category 3.1), derived from Zhang Zhongjing's Treatise on Febrile Diseases, with R&D investment of approximately 5.91 million yuan.复星医药子公司河北万邦复临药业的芍药甘草汤颗粒（中药3.1类）获国家药监局批准，处方源于张仲景《伤寒论》，累计研发投入约591万元。
2026-08-03Subsidiary Fosun Wanbang received NMPA approval for its self-developed Empagliflozin/Metformin Hydrochloride Sustained-Release Tablets (III) to improve glycemic control in adults with type 2 diabetes; cumulative R&D investment ~RMB 17.92 million.控股子公司复星万邦自主研发的恩格列净二甲双胍缓释片（III）获国家药监局批准，用于改善2型糖尿病成人患者血糖控制；累计研发投入约1792万元。
2026-08-03Subsidiary Suzhou Erye received NMPA approval for its Compound Polyethylene Glycol (3350) Electrolyte Powder for chronic constipation in children aged 1-11 and fecal impaction in children aged 5-11; cumulative R&D investment ~RMB 2.62 million.控股子公司苏州二叶的复方聚乙二醇（3350）电解质散获国家药监局批准，用于治疗1-11岁儿童慢性便秘及5-11岁儿童粪便嵌塞；累计研发投入约262万元。
2026-08-07Subsidiary Shanghai Chaohui received NMPA approval for its Dobutamine Hydrochloride Injection for short-term supportive treatment of heart failure due to decreased myocardial contractility in organic heart disease.控股子公司上海朝晖药业的盐酸多巴酚丁胺注射液获国家药监局批准，用于器质性心脏病时心肌收缩力下降引起的心力衰竭的短期支持治疗。
2026-08-07Subsidiary Fosun Pharma (Xuzhou) received NMPA approval for its self-developed Levalbuterol Hydrochloride Nebulization Solution for bronchospasm in adults and children over 6; 2025 China sales ~RMB 73 million.控股子公司复星医药（徐州）自主研发的盐酸左沙丁胺醇雾化吸入溶液获国家药监局批准，用于治疗或预防成人及6岁以上儿童可逆性气道阻塞性疾病引起的支气管痉挛；2025年中国境内销售额约0.73亿元。
Innovative drug pipeline (non-Henlius)创新药管线（非复宏汉霖）
25 · 2024-01-15 → 2026-08-13
▾
Clinical trial approvals and development updates for innovative drugs from various Fosun subsidiaries.来自复星多家子公司的创新药临床试验批准和开发进展。
2024-01-15Subsidiary Zhejiang Xinghao Pengbo Pharma received NMPA clinical trial approval for XH-S004 tablet for non-cystic fibrosis bronchiectasis; Phase I planned in China.控股子公司浙江星浩澎博医药获国家药监局批准XH-S004片用于非囊性纤维化支气管扩张症的临床试验，拟开展I期临床。
2024-01-25Subsidiary Fosun Pharma Industry received NMPA clinical trial approval for FCN-338 tablet (Bcl-2 inhibitor) combined with dexamethasone for systemic light-chain amyloidosis; Phase II planned in China.控股子公司复星医药产业获国家药监局批准FCN-338片联合地塞米松用于系统性轻链型淀粉样变性的临床试验，拟开展II期临床。
2024-02-29Fosun Pharma received NMPA approval to initiate a Phase II clinical trial for FCN-338 tablets (Bcl-2 inhibitor) combined with FCN-647 tablets for chronic lymphocytic leukemia/small lymphocytic lymphoma.复星医药获国家药监局批准开展FCN-338片联合FCN-647片治疗慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的II期临床试验。
2024-03-07Subsidiary Jiangsu Star Shengxin Hui Pharmaceutical received NMPA clinical trial approval for XS-02 capsules for advanced solid tumors; global first-in-class small molecule inhibitor targeting this pathway.控股子公司江苏星盛新辉医药获国家药监局批准XS-02胶囊用于晚期实体瘤的临床试验；全球尚无同靶点小分子抑制剂获批。
2024-03-07Subsidiary Shanghai Jing Shan Biotechnology received NMPA clinical trial approval for GCK-01 cell injection (universal NK cell therapy) for relapsed/chemotherapy-resistant follicular lymphoma; first domestically approved universal NK cell therapy for this indication.控股子公司上海精缮生物科技获国家药监局批准GCK-01细胞注射液（通用型NK细胞治疗药物）用于复发或化疗耐药的滤泡性淋巴瘤的临床试验；国内首款获批该适应症的通用型NK细胞治疗药物。
2024-03-29Subsidiary Fuhong Kanghe and Meiji Seika Pharma initiated two Phase III trials in China for OP0595 (Nacubactam) combined with cefepime or aztreonam for Gram-negative infections with limited treatment options.控股子公司复红康合与日本明治制果药业在中国启动OP0595（Nacubactam）联合头孢吡肟或氨曲南的两项III期临床试验，针对治疗方案有限的革兰氏阴性菌感染。
2024-04-29Fosun Pharma and Meiji Seika Pharma's jointly developed OP0595 combined with cefepime or aztreonam for adult aerobic Gram-negative infections started two Phase III trials in China.复星医药与明治制果药业共同开发的OP0595联合头孢吡肟或氨曲南用于成人需氧革兰氏阴性菌感染在中国启动两项III期临床研究。
2024-07-08Fosun Pharma's subsidiary Jiangsu Starsinghui received NMPA approval to initiate a Phase Ib/II clinical trial for FH-2001 capsule combined with Serplulimab injection in advanced solid tumors.复星医药控股子公司星盛新辉获国家药监局批准，开展FH-2001胶囊联合斯鲁利单抗注射液治疗晚期实体瘤的Ib/II期临床试验。
2024-09-27Subsidiary Xingsheng Xinhui received NMPA clinical trial approval for XS-04 tablets, a self-developed small-molecule drug for hematologic malignancies, especially DLBCL.控股子公司星盛新辉获国家药监局批准，就自主研发的小分子创新药XS-04片用于治疗血液系统恶性肿瘤（尤其是弥漫性大B细胞淋巴瘤）开展临床试验。
2025-01-14Subsidiary Zhejiang Xinghao Pengbo Pharma initiated Phase II clinical trial for XH-S003 capsule, a small-molecule inhibitor for IgA nephropathy and complement-related glomerular diseases; cumulative R&D investment ~98 million yuan.控股子公司浙江星浩澎博医药启动XH-S003胶囊II期临床试验，该药为小分子抑制剂，用于IgA肾病等补体异常激活相关肾小球疾病；累计研发投入约0.98亿元。
2025-02-06Subsidiary Xinghao Pengbo received NMPA clinical trial approval for XH-S004, a class 1 chemical drug for chronic obstructive pulmonary disease.控股子公司星浩澎博获国家药监局批准，同意XH-S004片（化药1类）用于慢性阻塞性肺疾病的临床试验。
2025-02-27NMPA approved clinical trial for XS-03 (oral PLK1 inhibitor) in combination with FOLFOX/FOLFIRI + bevacizumab for RAS-mutant metastatic colorectal cancer; Ib/II trial planned in China.国家药监局批准XS-03片（小分子口服PLK1抑制剂）与FOLFOX或FOLFIRI和贝伐珠单抗联合用于RAS突变转移性结直肠癌的Ib/II期临床试验。
2025-03-13Subsidiary Xinghao Pengbo receives NMPA approval to conduct Phase II clinical trial for XH-S003 capsule (self-developed small-molecule complement inhibitor) for paroxysmal nocturnal hemoglobinuria (PNH); cumulative R&D investment approx. RMB 106 million.控股子公司星浩澎博获国家药监局批准开展XH-S003胶囊（自主研发的补体系统小分子抑制剂）用于阵发性睡眠性血红蛋白尿症的II期临床试验，累计研发投入约1.06亿元。
2025-04-07Subsidiary Fosun Pharma (Xuzhou) receives NMPA approval to start clinical trial for self-developed CMC-2310 oral film for schizophrenia in adults and children over 13.控股子公司复星医药（徐州）获国家药监局批准，就自主研发的CMC-2310口溶膜用于精神分裂症开展临床试验。
2025-05-30Subsidiary Zhejiang Xinghao Pengbo initiated a Phase II trial in China for XH-S004 (oral DPP-1 inhibitor) for non-cystic fibrosis bronchiectasis; cumulative R&D ~RMB 61 million.控股子公司浙江星浩澎博医药在中国启动XH-S004（口服DPP-1抑制剂）用于非囊性纤维化支气管扩张症的II期临床试验；累计研发投入约0.61亿元。
2025-12-03Subsidiary Fosun Pharma Industrial received NMPA IND approval for FXS887 (FXS0887), an oral small-molecule ATR inhibitor, for advanced malignant solid tumors; Phase I trial in China.子公司复星医药产业获国家药监局批准FXS887片（FXS0887，口服小分子ATR抑制剂）用于晚期恶性实体瘤的临床试验，拟在中国开展I期试验。
2025-12-12Subsidiary Zhaohui Pharma received NMPA IND approval for ketoprofen patch for Phase III trial in analgesia and anti-inflammation (e.g., low back pain, osteoarthritis).子公司朝晖药业获国家药监局批准酮洛芬贴剂开展III期临床试验，用于镇痛消炎（如腰痛、骨关节炎）。
2026-03-13Subsidiary Fosun Pharma Industrial received NMPA approval for clinical trial of FXS0683 tablets (oral Bcl-2 inhibitor) for hematologic malignancies; cumulative R&D investment ~RMB 27 million as of Feb 2026.控股子公司复星医药产业获国家药监局批准，FXS0683片（口服Bcl-2抑制剂）用于血液系统恶性肿瘤开展临床试验；截至2026年2月累计研发投入约0.27亿元。
2026-03-16Subsidiary Shanghai Junji Health Technology received NMPA approval for clinical trial of LBP-ShC4 (live biotherapeutic product) for androgenetic alopecia (AGA); cumulative R&D investment ~RMB 20 million as of Feb 2026.控股子公司上海菌济健康科技有限公司获国家药监局批准，LBP-ShC4（活体生物治疗产品）用于雄激素脱发开展临床试验；截至2026年2月累计研发投入约0.20亿元。
2026-03-16Subsidiary Henlius received NMPA approval for clinical trial of HLX07 (anti-EGFR mAb) combined with serplulimab and chemotherapy for advanced squamous non-small cell lung cancer (sqNSCLC); cumulative R&D investment ~RMB 93 million as of Feb 2025.控股子公司复宏汉霖获国家药监局批准，HLX07（重组抗EGFR人源化单克隆抗体注射液）联合斯鲁利单抗注射液和化疗用于晚期鳞状非小细胞肺癌开展临床试验；截至2025年2月累计研发投入约0.93亿元。
2026-06-04Fosun Pharma's oral small-molecule innovative drug FXS0683 for hematologic malignancies completed first patient dosing in a Phase I clinical trial in China.复星医药自主研发的口服小分子创新药FXS0683用于血液系统恶性肿瘤的中国I期临床试验完成首例患者给药。
2026-07-15NMPA approved Fosun Pharma (Shenzhen)'s IND for FXR0906, a liver-targeted siRNA drug for hypertriglyceridemia; first-in-class in China; cumulative R&D investment ~RMB 71M.国家药监局批准复星医药（深圳）的FXR0906（肝靶向siRNA药物）用于治疗高甘油三酯血症的临床试验；中国境内同类首创；累计研发投入约7100万元。
2026-07-24NMPA approved Fosun Wanbang's IND for DM1001, a chemical drug for adult idiopathic Parkinson's disease; cumulative R&D investment ~RMB 6.95M; same compound's China sales were ~RMB 375M in 2025.国家药监局批准复星万邦的DM1001制剂用于治疗成人特发性帕金森病的临床试验；累计研发投入约695万元；相同化合物2025年中国境内销售额约3.75亿元。
2026-08-07Registered a Phase III trial for FXS6837, a CFB inhibitor, versus eculizumab in ~90 treatment-naive paroxysmal nocturnal hemoglobinuria patients.登记了一项FXS6837（CFB抑制剂）对比依库珠单抗用于约90例未接受过补体抑制剂治疗的阵发性睡眠性血红蛋白尿症患者的III期临床试验。
2026-08-13Subsidiary Fosun Pharma Industry initiated a Phase II clinical trial in China for FXS7553, a self-developed oral DPP-1 inhibitor, for chronic obstructive pulmonary disease; cumulative R&D investment ~RMB 151 million.控股子公司复星医药产业就自主研发的口服DPP-1抑制剂FXS7553用于治疗慢性阻塞性肺疾病在中国境内启动II期临床试验；累计研发投入约1.51亿元。
Share buybacks & incentives股份回购与激励
15 · 2024-01-16 → 2026-03-24
▾
Share repurchases, cancellations, equity incentive plans, and related shareholder transactions.股份回购、注销、股权激励计划及相关股东交易。
2024-01-1677.41万股股权激励限售股份于2024年1月16日解禁上市，占总股本0.03%。77.41万股股权激励限售股份于2024年1月16日解禁上市，占总股本0.03%。
2024-03-12Controlling shareholder Fosun High Technology cumulatively bought back 720,000 A-shares (0.03% of total shares) for ~RMB 20.08 million under a planned RMB 100 million+ buyback program; period half-over, 20.08% of lower limit completed.控股股东复星高科技累计增持72万股A股（占总股本0.03%），金额约2008万元，增持计划期间过半，完成下限的20.08%。
2024-08-07Fosun Pharma's board approved repurchase and cancellation of 1,072,246 A-share restricted shares for total RMB 22.83 million due to employee departures and retirement.复星医药董事会批准回购注销1,072,246股A股限制性股票，总价2283万元，因员工离职和退休。
2024-09-03Parent company Fosun Hi-Tech increased its stake in Fosun Pharma by purchasing 885,000 A-shares at an average price of RMB 22.594, raising its holding from 41.80% to 41.85%.母公司复星高科增持复星医药885,000股A股，买入均价22.594元，持股比例由41.80%升至41.85%。
2024-09-13Parent company Fosun Hi-Tech completed its A-share increase plan, cumulatively purchasing 4,295,000 A-shares for approximately RMB 101.19 million.控股股东复星高科技增持计划实施完毕，累计增持4,295,000股A股，金额约1.01亿元。
2024-11-22Fosun Pharma's subsidiary Jiankang Rehabilitation implemented equity incentive plan, granting 2 million yuan worth of partnership shares to 3 directors and senior executives, constituting a related-party transaction.复星医药控股子公司健嘉康复实施股权激励计划，向3名董事及高级管理人员授出合计200万元的跟投平台合伙份额，构成关联交易。
2025-05-28Fosun Pharma repurchased and cancelled 897,140 restricted A-shares (RMB 19.1 million) under the 2022 incentive plan due to departures and unmet 2024 performance targets.复星医药回购注销897,140股限制性A股（金额1910万元），原因为激励对象离职及2024年业绩考核未达标。
2025-06-07Fosun Pharma completed the repurchase and cancellation of 897,140 A-share restricted shares under the 2022 incentive plan, reducing registered capital to RMB 2.670 billion.复星医药完成2022年限制性A股激励计划下897,140股的回购注销，注册资本减至26.70亿元。
2025-06-24Fosun Pharma held 2024 AGM and class meetings, approved 21 resolutions including profit distribution, director election, share buyback authorization, and cancellation of supervisory board.复星医药召开2024年度股东会及类别股东会，审议通过21项议案，包括利润分配、董事选举、回购授权及取消监事会。
2025-06-24Fosun Pharma's 2024 AGM approved a general mandate to repurchase A/H shares (A-share approval rate 99.67%, H-share 99.99%) and new share issuance authorization (97.53%).复星医药2024年度股东会通过回购A/H股一般性授权（A股赞成率99.67%，H股99.99%）及新增发行股份授权（97.53%）。
2025-08-25Fosun Pharma announced a new A+H share equity incentive plan, with A-share options priced at a minimum of RMB 27.93 per share and H-share restricted share units, keyed to net profit and innovative drug revenue.复星医药宣布启动新一轮A+H股股权激励计划，A股期权行权最低价27.93元/股，H股为受限制股份单位，业绩考核核心指标为归母净利润和创新药品收入。
2025-11-04Board approved 2025 A-share stock option incentive plan: 195 grantees, 4,535,100 options, exercise price RMB 27.93, effective up to 60 months with three vesting periods.董事会批准2025年A股股票期权激励计划：授予195人共453.51万份期权，行权价27.93元，有效期最长60个月，分三个行权期。
2025-11-04Board approved 2025 H-share restricted share unit plan: 195 grantees, 10,589,500 units, including Chairman Chen Yuqing 953,500 units and CEO Liu Yi 762,800 units.董事会批准2025年H股受限制股份单位计划：授予195人共1058.95万股，其中董事长陈玉卿95.35万股，首席执行官刘毅76.28万股。
2025-12-03A-share stock option grant: 4.45 million options granted to 182 persons on Dec 2, 2025; exercise price CNY 27.93/share.A股期权授予：2025年12月2日向182人授予445万份期权，行权价27.93元/股。
2026-03-24Board approved to propose to shareholders' meeting for general mandates to issue up to 20% additional A/H shares and repurchase up to 10% of A/H shares; also approved new credit facilities up to RMB 385 billion equivalent and disposal of listed shares up to 10% of net assets.董事会审议通过提请股东大会授予增发不超过20% A/H股和回购不超过10% A/H股的一般性授权；新增不超过等值385亿元授信额度；授权处置上市公司股份不超过净资产10%。
Investments & equity stakes投资与股权
15 · 2024-01-31 → 2026-04-24
▾
Investments in other companies, changes in equity stakes, and related capital increases.对其他公司的投资、股权变动及相关增资。
2024-01-31Company holds 74,456,137 shares of We Doctor Holdings Limited, about 5.7% stake.公司持有微医（We Doctor Holdings Limited）74,456,137股，持股比例约5.7%。
2025-01-04Fosun Pharma invested in Suzhou Aiyi Animal Health Products' Series C+ round (undisclosed amount), a leading pet vaccine company in China.复星医药参与苏州艾益动物药品有限公司C+轮融资（金额未披露），该公司是中国领先的宠物疫苗企业。
2025-01-07Fosun Pharma holds 74,456,137 shares of We Doctor Holdings Limited, representing approximately 5.77% stake.复星医药合计持有微医（We Doctor Holdings Limited）74,456,137股，持股比例约为5.77%。
Fosun Pharma holds 74,456,137 shares in We Doctor, a 5.77% stake复星医药：持有微医74,456,137股，持股比例5.77%↗Fosun Pharma holds 74,456,137 shares in We Doctor, about 5.77%复星医药：截至目前，公司（通过子公司）合计持有微医（We Doctor Holdings Limited）74,456,137股，持股比例约为5.77%↗ 2025-03-31Plans to invest RMB 270 million (or USD equivalent) to subscribe to 105,468,750 new shares of United Health Insurance, increasing its stake from 14.00% to 20.05%; IFC and ADB also participate in the capital increase.拟出资2.7亿元（或等值美元）认购联合健康险105,468,750股新增股份，持股比例由14.00%增至20.05%；国际金融公司（IFC）和亚洲开发银行（ADB）也参与本次增资。
2025-04-01Fosun Pharma, IFC and ADB each invest RMB 270 million to subscribe to new shares of Fosun United Health Insurance, raising Fosun Pharma's stake from 14% to 20.05%.复星医药、国际金融公司（IFC）及亚洲开发银行（ADB）各出资2.7亿元认购复星联合健康保险新增股份，复星医药持股比例从14%提升至20.05%。
2025-04-11Fosun Pharma transfers 54% equity in Shanghai Fujian (上海复健) to Fosun High Technology and individuals for approx. RMB 26.54 million, reducing its stake to 45% and turning it into a joint venture.复星医药以约2653.97万元向复星高科技等转让上海复健54%股权，持股降至45%，转为合营公司。
2025-05-14Fosun Pharma led the A+ round financing of Salus Bio (Shenzhen), a domestic gene sequencer maker; funds will be used for registration, capacity expansion and international market expansion.复星医药领投深圳赛陆医疗A+轮融资，资金用于国产测序平台注册申报、产能扩建及国际市场拓展。
2025-07-22Fosun Pharma plans to invest in a nuclear medicine platform company Xingrui Jingxuan with initial registered capital of RMB 133.5M; Fosun to contribute RMB 120M for ~89.89% stake; includes follow-on investment and incentive plan for key personnel.复星医药拟参与投资设立核药业务平台企业星睿菁烜，初始注册资本1.335亿元，复星出资1.2亿元持股约89.89%，同步实施跟投及首期激励计划。
2025-08-06Fosun Pharma and Fujian Capital invested in Hengtai Bio's angel round to support its drug production innovation.复星医药与复健资本投资衡泰生物天使轮，支持其药品生产创新。
2025-08-20Fosun Pharma co-founded Shenzhen Hengtai Bio-Technology Co., Ltd. with a registered capital of RMB 20 million, holding drug retail and other operations.复星医药等共同设立深圳衡泰生物科技有限公司，注册资本2000万元，含药品零售等业务。
2025-08-28Fosun Pharma co-founded Chengdu Xingrui Jingxuan Biotechnology Co., Ltd. with a registered capital of RMB 134 million, covering radioactive solid waste treatment and other operations.复星医药等共同设立成都星睿菁烜生物科技有限公司，注册资本1.34亿元，含放射性固体废物处理等业务。
2025-10-28Fosun Pharma set up nuclear medicine platform Xingrui Jingxuan (星睿菁烜) for radiopharmaceutical R&D and collaboration.复星医药设立核药业务平台星睿菁烜，布局诊疗一体化核药产品。
2025-12-16Shanghai Stock Exchange issued a regulatory letter to Fosun Pharma regarding its investment in Green Valley Pharma.上交所就复星医药对外投资绿谷医药相关事项下发监管工作函。
2025-12-23Fosun Pharma responded to the SSE regulatory letter on Green Valley Pharma investment: disclosed GV-971 cumulative sales of CNY 1.92B, revised confirmatory trial plan (48-week double-blind, 1950 patients), expected enrollment completion by end of 2027, data readout in early 2029.复星医药回复上交所关于绿谷医药投资的监管函：披露甘露特钠胶囊累计销售额19.2亿元，修订确证性试验方案（48周双盲、1950例），预计2027年底完成入组，2029年初读出数据。
2026-04-24Fosun Pharma (via Fujian Capital) co-led the over-100-million-yuan Series A round in Aoming Xingcheng (Hangzhou) Biotechnology, an AI-driven multi-omics cancer diagnostics company.复星医药（通过复健资本）联合领投奥明星程（杭州）生物科技有限公司超亿元A轮融资，该公司为AI驱动的多组学肿瘤诊断企业。
Strategic partnerships & collaborations战略合作与联盟
17 · 2024-02-07 → 2026-04-28
▾
Strategic cooperation agreements, MOUs, and partnerships with various entities for development and commercialization.与各方在开发和商业化方面的战略合作协议、备忘录及伙伴关系。
2024-02-07Fosun Pharma signed a strategic cooperation memorandum with Beijing Children's Hospital (National Children's Medical Center) on pediatric drug R&D, manufacturing, and technology transfer.复星医药与国家儿童医学中心北京儿童医院签署战略合作备忘录，在儿童药品研发、生产制造、成果转化等方面展开合作。
2024-07-01Fosun Pharma and Beikong Group signed a cooperation framework agreement to jointly develop cultural tourism, commercial projects, industrial investment, and real estate in Beijing's sub-center, including Zhangjiawan Ancient Town project.复星高科与北投集团签署合作意向框架协议，共同开发北京城市副中心的文旅、商业、产业投资及地产项目，包括张家湾古镇项目。
2024-09-24Fosun Pharma signed a strategic cooperation framework agreement with Zhongheng Group and Nanning Chan Tou to jointly set up a platform company for exporting mature drugs to ASEAN countries.复星医药与中恒集团、南宁产投统一公司签署战略合作框架协议，共同出资设立平台公司，开展东盟国家成熟药产品出海贸易。
2024-10-22Fosun Pharma signed a strategic cooperation framework agreement with Beijing Economic-Technological Development Area to establish an innovative medical device headquarters, an incubation center, and a production-sales base for drugs and devices.复星医药与北京经济技术开发区签署战略合作框架协议，将设立创新医疗器械总部、打造创新药械孵化中心、培育成熟药械产销基地。
2025-02-26Fosun High Technology signed a comprehensive strategic cooperation agreement with China Minsheng Bank covering financing, investment banking, cross-border settlement, supply chain finance, etc.复星高科技与中国民生银行签署全面战略合作协议，围绕融资授信、投行业务、国际结算、供应链金融等展开合作。
2025-03-14Enters strategic cooperation with Salus Bio (SaiLu Medical) on product R&D, platform building, and application promotion; Salus Bio's sequencing platform production base in the Yangtze River Delta (Shanghai Baoshan) commences operation.与赛陆医疗达成战略合作，在产品研发、平台搭建、应用推广等方面开展合作；赛陆医疗测序平台在长三角（上海宝山）的生产基地投入运营。
2025-04-09Fosun Pharma and Salus Biomed (赛陆医疗) reach a strategic cooperation on product R&D, platform building, and application promotion in precision medicine and sequencing platforms.复星医药与赛陆医疗达成战略合作，在产品研发、平台搭建、应用推广等方面开展合作，涉及精准医疗和测序平台。
2025-04-28Fosun Pharma announces strategic cooperation with Saudi healthcare group Fakeeh Care Group to jointly advance biologics and CAR-T cell therapy in Saudi Arabia.复星医药宣布与沙特医疗集团Fakeeh Care Group达成战略合作，共同推进生物药和CAR-T细胞疗法在沙特落地。
2025-06-16Fosun Pharma and Teva Pharmaceutical Industries announced strategic collaboration to develop anti-PD1-IL2 ATTENUKINE therapy TEV-56278; Fosun gets exclusive rights in China and select Southeast Asian countries.复星医药与梯瓦制药宣布就抗PD1-IL2 ATTENUKINE疗法TEV-56278的开发达成战略合作，复星获得中国及特定东南亚国家的独家许可。
2025-09-03Fosun Pharma President Wen Deyong met with Nagqu city officials to discuss cooperation in the full-industry-chain development of Cordyceps sinensis and plateau cultural tourism, together with SDIC Chuangyi Industrial Fund Management.复星医药总裁文德镛与那曲市官员会面，商讨与国投创益产业基金合作开发冬虫夏草全产业链及高原文化旅游。
2025-10-22Fosun Pharma and Helsinn Group signed strategic cooperation for local production of antiemetic fosnetupitant/palonosetron concentrate in China.复星医药与赫尔森集团达成战略合作，在中国本地化生产止吐药物磷奈匹坦帕洛诺司琼注射用浓溶液。
2025-10-30Fosun Pharma and Fangzhou Jianke (方舟健客) partnered to apply AI in psoriasis management, covering education, digital marketing, and chronic disease care.复星医药与方舟健客合作，将AI应用于银屑病管理，涵盖学术、科普、数字化营销及慢病全流程。
2025-11-06At CIIE, Fosun Pharma and Leo Cancer Care signed strategic cooperation agreement to commercialize Marie® upright particle therapy indoor system in China.进博会上，复星诊疗科技与Leo Cancer Care签署战略合作协议，推动Marie®立式粒子治疗室内系统在中国的商业化落地。
2025-11-06At CIIE, Fosun Pharma launched a combined Parkinson's treatment solution: Opicapone (third-generation COMT inhibitor) plus 'Magnetic Resonance-guided Focused Ultrasound' (MRgFUS) system.进博会上，复星医药发布帕金森病联合治疗方案：奥吡卡朋（第三代COMT抑制剂）联合“磁波刀”（磁共振引导聚焦超声）系统。
2025-11-25Fosun Pharma signed a strategic cooperation agreement with Shanghai Rizhi Pharma (Shanghai RuiZhi YiYao) to leverage its full-chain R&D service capabilities for drug development.复星医药与上海睿智医药达成战略合作，借助其全链条研发服务能力提升药物研发效率与质量。
2025-11-28Fosun Pharma and Chongqing Pharmaceutical Holding (重药控股) signed a mutual supply framework agreement for 2026-2028, with sales caps of RMB 1.4B/1.7B/2.0B for 2026/2027/2028.复星医药与重药控股签署2026-2028年互供框架协议，销售产品上限2026年14亿元、2027年17亿元、2028年20亿元。
2026-04-28Fosun Pharma signed a strategic cooperation MOU with Arcera Life Sciences (Abu Dhabi) for licensing, technology development, and neuroscience innovation, including potential JV in Abu Dhabi for small molecules, biologics, siRNA, and cell/gene therapy.复星医药与阿布扎比Arcera Life Sciences签署合作备忘录，聚焦许可授权、技术开发及神经科学创新，包括探索在阿布扎比成立合资公司，涉及小分子、生物药、siRNA、细胞与基因治疗。
Other developments其他动态
24 · 2024-02-20 → 2026-04-29
▾
Assorted developments not part of a running storyline.未归入某条故事线的零散动态。
2024-02-20The Binhu Fosun Humanoid Robot Industrial Park project, with a total investment of RMB 1.26 billion, officially started construction in Wuxi, focusing on humanoid robots, smart manufacturing, and IC industries.总投资12.6亿元的滨湖复星人形机器人产业园项目在无锡正式开工，聚焦人形机器人、智能制造、集成电路等产业链。
2024-07-08Fosun Pharma's subsidiary Wanbang Pharmaceutical passed EU GMP on-site inspection for its freeze-dried formulation production line (Line 4, target product: Parecoxib Sodium for Injection), receiving certificate from Dutch Health and Youth Care Inspectorate.复星医药旗下万邦医药冻干制剂生产线（注射剂生产线4，目标产品注射用帕瑞昔布钠）通过欧盟GMP现场检查，获荷兰卫生监督机构证书。
2024-07-10Fosun Pharma's subsidiary Jiangsu Fosun filed an arbitration claim against Allist Pharmaceuticals at Shanghai International Arbitration Center, seeking RMB 255 million in damages over a terminated exclusive promotion agreement for Furmonertinib.复星医药子公司江苏复星向上海国际仲裁中心对艾力斯提起仲裁，要求赔偿2.55亿元，涉及终止的伏美替尼独家推广协议争议。
2024-07-22Fosun Pharma's strategic partner Beijing Weici Technology's innovative medical device, helium-free magnetoencephalography system (128-channel, Marvel MEG), received NMPA marketing approval.复星医疗器械战略伙伴北京未磁科技自主研发的无液氦脑磁图系统（128通道，Marvel MEG）获国家药监局批准上市。
2024-08-22Fosun Pharma's JV Fosun Yishite with Insightec advances commercialization of MR-guided focused ultrasound brain treatment system in China, Hong Kong, and Macau.复星医药与Insightec的合资公司复星医视特推进磁共振引导聚焦超声脑部治疗系统在中国境内及港澳市场的商业化。
2024-08-27Fosun Pharma's overseas revenue reached RMB 5.51 billion in H1 2024, up 15.13% YoY, accounting for 26.93% of total revenue.复星医药2024年上半年海外收入55.1亿元，同比增长15.13%，占总营收26.93%。
2024-10-20Fosun Pharma disclosed that its subsidiary Jiangsu Fosun filed an arbitration in June 2024 against Allist (Shanghai) over a dispute regarding the exclusive promotion agreement for lung cancer drug Furmonertinib, seeking 255 million yuan in damages and fees.复星医药披露，其控股子公司江苏复星于2024年6月就肺癌药物伏美替尼的独家推广协议纠纷向艾力斯提起仲裁，索赔合计2.55亿元。
2024-11-16Fosun Pharma issued an initiative to actively respond to drug traceability code medical insurance regulatory applications, committing to 100% collection and upload of drug traceability codes by all pharmaceutical business enterprises.复星医药发布倡议书，积极响应药品追溯码医保监管应用，承诺所有医药经营企业100%采集并上传药品追溯码。
2024-12-11Fosun Pharma renewed daily connected transaction framework agreements with Fosun International for 2025, setting transaction caps (e.g., sales up to RMB 35 million, purchases up to RMB 30 million).复星医药与复星国际续签2025年日常关联交易框架协议，设定交易上限（如销售3500万元、采购3000万元）。
2025-01-14Fosun subsidiary acquired 100% of Quanzhou Xingyao Commercial Management (formerly Wanda commercial management subsidiary) via Yantai Xingruiying Commercial Management.复星集团旗下烟台星颐瑞迎商业管理有限公司收购泉州星耀商业管理有限公司（原万达商管旗下公司）100%股权。
2025-01-17Media reported that Fosun subsidiary Yuyuan Inc. is considering a Hong Kong secondary listing, potentially seeking over USD 300 million (approx. HKD 2.34 billion).据媒体报道，复星子公司豫园股份考虑在香港第二上市，或寻求融资逾3亿美元（约23.4亿港元）。
2025-04-08Fosun Pharma states that the US reciprocal tariff policy exempts pharmaceutical products, so the impact on its business is limited.复星医药表示美国对等关税政策豁免医药产品，对公司业务影响有限。
2025-05-09Subsidiary Shanghai MicroH Therapeutics received US FDA approval for an IND to start Phase I trial of LBP-ShC4, a live biotherapeutic product for androgenetic alopecia (AGA); no such product is approved globally.控股子公司上海菌济健康科技获美国FDA批准开展LBP-ShC4的I期临床试验，该活体生物治疗产品拟用于雄激素脱发（AGA）；全球尚无同类产品获批。
2025-09-03Fosun Wealth Holdings tokenized Hong Kong-listed shares of Sisram Medical (medical technology) worth USD 328 million, deployed via Vaulta, Solana, Ethereum, and Sonic.复星财富集团将以色列医疗科技公司Sisram Medical的香港上市股份代币化，价值3.28亿美元，通过Vaulta、Solana、Ethereum和Sonic部署。
2025-09-09Morgan Stanley upgraded Fosun Pharma A-share and H-share ratings to 'Overweight', raising A-share target price to RMB 42 and H-share target to HKD 33, citing undervalued innovative drug pipeline and financial optimization from non-core asset divestitures.摩根士丹利上调复星医药A股和H股评级至“超配”，A股目标价上调至42元人民币，H股目标价上调至33港元，理由为创新药管线被低估及非核心资产剥离带来的财务优化。
2025-09-10CLSA raised Fosun Pharma A-share target price to RMB 40.2 and H-share target to HKD 29.60, maintaining 'Outperform' rating, citing strong Q2 2025 performance with revenue up 7.2% QoQ and net profit up 22.5% QoQ driven by innovative drug sales.中信里昂证券上调复星医药A股目标价至40.2元人民币，H股目标价至29.60港元，维持“跑赢大市”评级，理由为2025年第二季度营收环比增7.2%、净利润环比增22.5%，受创新药销售驱动。
2025-10-08Fosun Pharma's Middle East office and JV Fosunhenlius Middle East United Company inaugurated in Jeddah, Saudi Arabia, with SVax for MENAT region biosimilar commercialization.复星医药中东办公室及合资公司Fosunhenlius Middle East United Company在沙特吉达揭牌，与SVax合作在MENA地区商业化生物类似药。
2025-10-31Fosun Pharma to debut Marie® upright particle therapy system at 8th China International Import Expo (CIIE).复星医药将在第八届进博会上首展Marie®立式粒子治疗室内系统。
2025-11-30Board approved 2026 related-party transaction estimates totaling RMB 366.5M, covering sales, services, property leasing with Fosun Foundation, United Health Insurance, Intuitive Fosun, etc.董事会批准2026年度日常关联交易预计总额3.665亿元，涉及向复星公益基金会、联合健康险、直观复星等关联方的销售、服务及物业租赁。
2026-03-03Fosun Wealth International Holdings partnered with Unified Labs on offshore RWA tokenization on-chain lending risk management and FUSD on-chain financial market construction.复星财富国际控股与Unified Labs合作，围绕境外实体资产代币化（RWA）的链上借贷风险管理及FUSD链上金融市场建设展开合作。
2026-03-17Indirect subsidiary Suzhou Erye Pharmaceutical obtained environmental approval for expansion project of heparin series preparations production, with total investment of RMB 35 million.间接控股子公司苏州二叶制药有限公司扩建生产肝素系列制剂项目环评审批获原则同意，项目总投资额达3500万元。
2026-03-24Fosun Pharma's total upfront payments from out-licensing in 2025 exceeded USD 260 million, with potential milestone payments exceeding USD 3.8 billion.复星医药2025年全年对外许可首付款总金额超2.6亿美元，潜在里程碑总金额超38亿美元。
2026-04-07Subsidiary Gansu Fosun Building Materials completed a new sintered brick production plant in Kangle County with total investment of 260 million yuan, annual capacity of 270 million bricks, and expected annual output value of 198 million yuan.子公司甘肃复星建材在康乐县完成新型烧结砖生产项目竣工投产，总投资2.6亿元，年产2.7亿块砖，预计年产值1.98亿元。
2026-04-29Fosun Pharma was recognized as a 'Shanghai Innovative Enterprise Headquarters' by the Shanghai municipal government, among 44 companies in the third batch.复星医药获上海市政府认定为第三批“上海市创新型企业总部”，共44家企业入选。
Henlius pipeline & approvals复宏汉霖管线与获批
61 · 2024-02-29 → 2026-08-17
▾
Clinical trials, regulatory approvals, and label expansions for Henlius's biosimilar and innovative drug pipeline.复宏汉霖生物类似药和创新药管线的临床试验、监管批准及适应症扩展。
2024-02-29Fosun Pharma's subsidiary Henlius' self-developed汉达远 (adalimumab injection) received supplementary application acceptance from the NMPA for 4 new indications: polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease.复星医药控股子公司复宏汉霖自主研发的汉达远（阿达木单抗注射液）新增4项适应症补充申请获国家药监局受理。
2024-03-12Subsidiary Henlius received NMPA clinical trial approval for HLX6018 (recombinant anti-GARP/TGF-β1 humanized monoclonal antibody) for idiopathic pulmonary fibrosis; global first-in-class targeting GARP/TGF-β1 complex.控股子公司复宏汉霖获国家药监局批准HLX6018（重组抗GARP/TGF-β1人源化单克隆抗体）用于特发性肺纤维化的临床试验；全球尚无靶向GARP/TGF-β1复合物的单抗获批。
2024-04-17Fosun Pharma subsidiary Henlius received NMPA approval for Phase II clinical trial of HLX53 (anti-TIGIT Fc fusion protein) combined with serplulimab and bevacizumab for first-line advanced/metastatic hepatocellular carcinoma.复星医药子公司复宏汉霖获国家药监局批准开展HLX53联合汉斯状和汉贝泰一线治疗晚期/转移性肝细胞癌的II期临床试验。
2024-04-29Trastuzumab injection (Han Qu You) received US FDA approval in April 2024 for HER2-overexpressing breast cancer and gastric cancer, becoming the first Chinese biosimilar approved in China, EU, and US.注射用曲妥珠单抗（汉曲优）2024年4月获美国FDA批准上市，用于HER2过表达乳腺癌和胃癌，成为首个在中国、欧盟、美国获批的国产生物类似药。
2024-05-06Subsidiary Henlius received FDA approval for IND of HLX22 (anti-HER2 mAb) combined with trastuzumab and chemotherapy for first-line treatment of HER2-positive advanced gastric cancer, planning a Phase III trial in the US.控股子公司复宏汉霖获美国FDA批准HLX22（抗HER2单抗）联合曲妥珠单抗及化疗一线治疗HER2阳性晚期胃癌的临床试验，拟在美国开展III期试验。
2024-05-14Subsidiary Henlius received NMPA approval to conduct Phase I and global multi-center Phase III trials in China for HLX78 (lasofoxifene) combined with abemaciclib for ER+/HER2- breast cancer with ESR1 mutation.控股子公司复宏汉霖获国家药监局批准，在中国开展HLX78（拉索昔芬片）联合阿贝西利治疗ESR1突变ER+/HER2-乳腺癌的I期和全球多中心III期临床试验。
2024-05-22Subsidiary Henlius received NMPA approval for supplementary application of汉达远 (adalimumab injection) adding 4 new indications: polyarticular juvenile idiopathic arthritis, pediatric plaque psoriasis, Crohn's disease, and pediatric Crohn's disease.控股子公司复宏汉霖自主研发的汉达远（阿达木单抗注射液）获国家药监局批准新增4项适应症：多关节型幼年特发性关节炎、儿童斑块状银屑病、克罗恩病及儿童克罗恩病。
2024-08-27Fosun Pharma's biosimilar trastuzumab (Han Qu You) obtained 3 indications approved by US FDA, covering breast and gastric cancer, becoming the first Chinese biosimilar approved in China, EU, and US.复星医药生物类似药汉曲优（注射用曲妥珠单抗）3项适应症获美国FDA批准，涵盖乳腺癌和胃癌，成为首个在中欧美三地获批的国产生物类似药。
2024-08-27Fosun Pharma's biosimilar adalimumab (Han Da Yuan) obtained 4 new indications approved by NMPA, covering all 8 indications of the originator in China.复星医药生物类似药汉达远（阿达木单抗注射液）4项新增适应症获国家药监局批准，至此覆盖原研药在中国全部8项适应症。
2024-08-27Fosun Pharma's denosumab biosimilar HLX14 had MAAs for 5 indications accepted by EMA.复星医药地舒单抗生物类似药HLX14的5项适应症上市许可申请获欧洲药品管理局受理。
2024-09-02Subsidiary Henlius received NMPA clinical trial approval for HLX17 (recombinant anti-PD-1 humanized monoclonal antibody injection) for multiple cancers including melanoma, NSCLC, esophageal cancer, etc.控股子公司复宏汉霖获国家药监局批准，就HLX17（重组抗PD-1人源化单克隆抗体注射液）用于治疗黑色素瘤、非小细胞肺癌等多种肿瘤开展临床试验。
2024-12-04Subsidiary Henlius received NMPA clinical trial approval for HLX22 (anti-HER2 mAb) combined with trastuzumab and chemo for HER2-expressing solid tumors.子公司复宏汉霖获国家药监局批准开展HLX22（抗HER2单抗）联合曲妥珠单抗和化疗治疗HER2表达实体瘤的临床试验。
2024-12-04Subsidiary Henlius received NMPA clinical trial approval for HLX43 (anti-PD-L1 ADC) as monotherapy or combination for advanced/metastatic solid tumors (Phase Ib/II).子公司复宏汉霖获国家药监局批准开展HLX43（抗PD-L1抗体偶联药物）单药或联合治疗晚期/转移性实体瘤的Ib/II期临床试验。
2024-12-04Subsidiary Henlius' pertuzumab biosimilar HLX11 registration application accepted by NMPA for HER2-positive breast cancer.子公司复宏汉霖的帕妥珠单抗生物类似药HLX11注册申请获国家药监局受理，用于HER2阳性乳腺癌。
2025-01-10Subsidiary Henlius received NMPA clinical trial approval for HLX43 (PD-L1 ADC) combined with serplulimab (Hansizhuang) for advanced/metastatic solid tumors; to conduct Ib/II trial in China.控股子公司复宏汉霖获国家药监局批准，开展注射用HLX43（PD-L1 ADC）联合斯鲁利单抗注射液（汉斯状）治疗晚期/转移性实体瘤的Ib/II期临床试验。
2025-02-06Henlius signed a license agreement with Dr. Reddy's for HLX15 (anti-CD38 biosimilar) in the US and 42 European countries; total up to USD 131.6 million (USD 33 million upfront + up to USD 98.6 million milestones) plus tiered royalties up to 8%.复宏汉霖与Dr. Reddy's签订许可协议，授予HLX15（抗CD38生物类似药）在美国及42个欧洲国家的开发、生产和商业化权利；总金额至多1.316亿美元（首付3300万美元+里程碑至多9860万美元）及不高于8%的分层特许权使用费。
2025-02-20Henlius' bevacizumab biosimilar (Hanbeita, LONGIVA) received marketing approval in Bolivia from AGEMED, becoming the fourth overseas-approved self-developed product.复宏汉霖贝伐珠单抗生物类似药汉贝泰（LONGIVA）获玻利维亚AGEMED批准上市，成为第四款海外获批的自研产品。
2025-03-19Subsidiary Henlius USA receives FDA Orphan Drug Designation for HLX22 (recombinant humanized anti-HER2 mAb) for gastric cancer treatment.控股子公司Henlius USA Inc.收到美国FDA孤儿药资格认定，用于胃癌治疗的HLX22（重组人源化抗HER2单克隆抗体注射液）。
2025-03-25Subsidiary Henlius receives NMPA clinical trial approval for HLX79 injection (human sialidase fusion protein) combined with rituximab for active glomerulonephritis; Phase II trial planned; cumulative R&D investment approx. RMB 140,000.控股子公司复宏汉霖获国家药监局批准开展HLX79注射液（人唾液酸酶融合蛋白）联合利妥昔单抗注射液用于活动期肾小球肾炎的II期临床试验，累计研发投入约14万元。
2025-04-29Subsidiary Henlius signs license agreement with Sandoz AG for HLX13 (anti-CTLA-4 mAb) in US, Europe (42 countries), Japan, Australia, Canada; up to USD 191 million in upfront and development milestones, plus up to USD 110 million in sales milestones and profit sharing.控股子公司复宏汉霖与Sandoz AG就HLX13（抗CTLA-4单抗）签署许可协议，授权区域包括美国、欧洲42国等，首付款及开发里程碑至多1.91亿美元，销售里程碑至多1.1亿美元，另有利润分成。
2025-05-16Subsidiary Henlius initiated a Phase I/III trial in China for HLX13 (ipilimumab biosimilar) as first-line treatment for unresectable advanced hepatocellular carcinoma.控股子公司复宏汉霖在中国启动伊匹木单抗生物类似药HLX13一线治疗不可切除晚期肝细胞癌的I/III期临床试验。
2025-05-26Subsidiary Henlius Europe GmbH received EU orphan drug designation for HLX22 (anti-HER2 mAb) for gastric cancer; cumulative R&D investment ~RMB 310 million.控股子公司Henlius Europe GmbH获欧盟委员会授予HLX22（抗HER2单抗）用于胃癌治疗的孤儿药资格认定；累计研发投入约3.1亿元。
2025-06-27Fosun Pharma subsidiary Henlius proposed to adopt share option plan and restricted share unit plan, granting up to 6.985 million options and RSUs to 279 grantees.复星医药控股子公司复宏汉霖拟采纳购股权计划及受限制股份单位计划，向279名激励对象授予最多698.5万份购股权及受限制股份单位。
2025-06-30Fosun Pharma subsidiary Henlius signed a license agreement with FBD for SIRPα-Fc fusion protein HCB101; up to $59 million upfront and milestones, plus up to $143 million commercial milestones.复星医药控股子公司复宏汉霖与FBD就SIRPα-Fc融合蛋白HCB101签订许可协议，首付款及里程碑付款最高5900万美元，另加最高1.43亿美元商业里程碑。
2025-07-01Subsidiary Henlius signed a license agreement with FBD Biologics for SIRPα-Fc fusion protein (HCB101) in China and SE Asia; up to USD 59M upfront and milestones plus up to USD 143M commercial milestones and royalties.子公司复宏汉霖与FBD Biologics就SIRPα-Fc融合蛋白（HCB101）在中国及东南亚地区签署许可协议，首付款及里程碑款最高5900万美元，另加最高1.43亿美元商业里程碑及销售提成。
2025-07-02Subsidiary Shanghai Henlius Biopharmaceutical received EU GMP certificate from Belgian FAMHP for pertuzumab injection (HLX11) and denosumab injection (HLX14); cumulative investment ~RMB 236M.子公司上海复宏汉霖生物医药获比利时联邦药品和保健产品管理局颁发的欧盟GMP证书，认证产品为帕妥珠单抗注射液（HLX11）和地舒单抗注射液（HLX14），累计投入约2.36亿元。
2025-08-07Fosun Pharma's subsidiary Henlius received US FDA approval for a Phase I trial of HLX43 (PD-L1 ADC) for thymic carcinoma, with cumulative R&D investment of ~RMB 182 million as of June 2025.复星医药子公司复宏汉霖获美国FDA批准开展HLX43（PD-L1 ADC）治疗胸腺癌的I期临床试验，截至2025年6月累计研发投入约1.82亿元。
2025-09-01Fosun Pharma subsidiary Henlius obtained US FDA approval for denosumab injection (HLX14) in two specifications (60mg/mL, 120mg/1.7mL) for five indications including postmenopausal osteoporosis; global sales of denosumab approx. USD 7.462 billion.复星医药子公司复宏汉霖获美国FDA批准地舒单抗注射液（HLX14）两种规格（60mg/mL、120mg/1.7mL），用于绝经后骨质疏松等五项适应症；地舒单抗全球销售额约74.62亿美元。
2025-09-08Fosun Pharma subsidiary Henlius received US FDA approval for Phase I trial of HLX17 (recombinant anti-PD-1 humanized monoclonal antibody, pembrolizumab biosimilar) for multiple resected solid tumors; cumulative R&D investment approx. RMB 176 million.复星医药子公司复宏汉霖获美国FDA批准开展HLX17（重组抗PD-1人源化单抗，帕博利珠单抗生物类似药）用于多种已切除实体瘤的I期临床试验；累计研发投入约1.76亿元。
2025-10-17Fosun Pharma's subsidiary Henlius' HLX43 (anti-PD-L1 ADC) received US FDA Orphan Drug Designation for thymic epithelial tumors (TETs).复星医药子公司复宏汉霖的HLX43（抗PD-L1 ADC）获美国FDA孤儿药资格认定，用于胸腺上皮肿瘤治疗。
2025-11-14Subsidiary Henlius' POHERDY® (pertuzumab biosimilar, HLX11) BLA approved by US FDA for HER2-positive metastatic breast cancer and early breast cancer (neoadjuvant/adjuvant).控股子公司复宏汉霖自主研发的POHERDY®（帕妥珠单抗生物类似药，HLX11）获美国FDA批准，用于HER2阳性转移性乳腺癌及早期乳腺癌新辅助/辅助治疗。
2025-11-17Fosun Pharma and Organon announced POHERDY® is the first and only PERJETA biosimilar approved in the US, interchangeable with the reference product.复星医药与Organon宣布POHERDY®成为美国首款且唯一的PERJETA生物类似药，可与原研产品互换使用。
2025-12-01Subsidiary Henlius received NMPA approval for IND of HLX37, a recombinant humanized anti-PD-L1/VEGF bispecific antibody injection, for advanced/metastatic solid tumors; Phase I trial to be initiated in China.子公司复宏汉霖获国家药监局批准HLX37注射液（重组人源化抗PD-L1与抗VEGF双特异性抗体）用于晚期/转移性实体瘤的临床试验，拟在中国境内开展I期试验。
2025-12-02Subsidiary Henlius' BLA for denosumab biosimilar HLX14 (Prolia reference) was accepted by NMPA; already approved in US, EU, UK.子公司复宏汉霖的地舒单抗生物类似药HLX14（参照普罗力）的上市申请获国家药监局受理；该药已在美国、欧盟、英国获批。
2025-12-09Subsidiary Henlius received NMPA approval for IND of HLX22 (anti-HER2 mAb) + HLX87 (HER2-ADC) for Phase II/III trial in first-line and neoadjuvant treatment of HER2+ breast cancer.子公司复宏汉霖获国家药监局批准HLX22（抗HER2单抗）联合HLX87（HER2-ADC）用于HER2阳性乳腺癌一线和新辅助治疗的II/III期临床试验。
2025-12-19Subsidiary Henlius received US FDA IND approval for HLX18 (nivolumab biosimilar) for Phase I trial in multiple solid tumors in the US.子公司复宏汉霖获美国FDA批准HLX18（纳武利尤单抗生物类似药）在美国开展多种实体瘤的I期临床试验。
2026-01-20Fosun Pharma's subsidiary Henlius received NMPA approval to conduct a Phase Ib/II clinical trial of HLX701 (recombinant SIRPα-IgG4 Fc fusion protein) combined with cetuximab and chemotherapy for advanced colorectal cancer; cumulative R&D investment about 76.09 million yuan.复星医药控股子公司复宏汉霖获国家药监局批准，开展HLX701（重组人SIRPα-IgG4 Fc融合蛋白注射液）联合西妥昔单抗和化疗治疗晚期结直肠癌的Ib/II期临床试验；累计研发投入约7609万元。
2026-01-27Fosun Pharma's subsidiary Henlius received NMPA approval for a Phase II clinical trial of HLX43 (PD-L1 ADC) combined with HLX07 and serplulimab for advanced solid tumors; cumulative R&D investment about 2.66 million yuan.复星医药控股子公司复宏汉霖获国家药监局批准，开展注射用HLX43联合HLX07及斯鲁利单抗注射液治疗晚期实体瘤的II期临床研究；累计研发投入约266万元。
2026-03-05Subsidiary Henlius received NMPA approval for Phase I clinical trial of HLX97 (KAT6A/B small molecule inhibitor) for advanced/metastatic solid tumors; cumulative R&D investment ~RMB 17.55 million as of Jan 2026.控股子公司复宏汉霖获国家药监局批准，HLX97（KAT6A/B小分子抑制剂）用于晚期/转移性实体瘤开展I期临床试验；截至2026年1月累计研发投入约1755万元。
2026-03-09Subsidiary Henlius received NMPA approval for Phase I clinical trial of HLX316 (B7-H3-targeted sialidase Fc fusion protein) for advanced/metastatic solid tumors; cumulative R&D investment ~RMB 68.72 million as of Jan 2026.控股子公司复宏汉霖获国家药监局批准，注射用HLX316（靶向B7-H3的唾液酸酶Fc融合蛋白）用于晚期/转移性实体瘤开展I期临床试验；截至2026年1月累计研发投入约6872万元。
2026-03-09Subsidiary Henlius received NMPA approval for Phase I clinical trial of HLX3901 (DLL3xDLL3xCD3xCD28 tetra-specific antibody) for advanced/metastatic solid tumors.控股子公司复宏汉霖获国家药监局批准，HLX3901注射液（DLL3xDLL3xCD3xCD28四特异性抗体）用于晚期或转移性实体瘤开展I期临床试验。
2026-03-20Subsidiary Henlius received NMPA approval for Phase I clinical trial of HLX18 (recombinant anti-PD-1 mAb, nivolumab biosimilar) for multiple solid tumors; cumulative R&D investment ~RMB 59 million as of Feb 2026.控股子公司复宏汉霖获国家药监局批准，HLX18（重组抗PD-1人源化单克隆抗体注射液，纳武利尤单抗生物类似药）用于多种实体瘤开展I期临床试验；截至2026年2月累计研发投入约0.59亿元。
2026-03-20Henlius' wholly-owned subsidiary Henlius Runlin signed a promotion service agreement with Fosun Yaohong for the promotion of Hanbeita (bevacizumab biosimilar) from Mar 20 to Dec 31, 2026.复宏汉霖全资附属公司复宏瑞霖与复星曜泓签订推广服务协议，于2026年3月20日至12月31日期间推广汉贝泰®（贝伐珠单抗生物类似药）。
2026-04-01Subsidiary Henlius received NMPA approval for Phase I trial of HLXTE-HAase02 (recombinant hyaluronidase injection) to enhance subcutaneous drug delivery; cumulative R&D investment ~27.33 million yuan.子公司复宏汉霖获国家药监局批准，开展HLXTE-HAase02（重组人透明质酸酶注射液）I期临床试验，用于促进皮下给药；累计研发投入约2673万元。
2026-04-01Subsidiary Henlius received NMPA approval for Phase I trial of HLX319 (pertuzumab-trastuzumab biosimilar, subcutaneous injection) for HER2-positive early/locally advanced breast cancer neoadjuvant therapy; cumulative R&D investment ~33.87 million yuan.子公司复宏汉霖获国家药监局批准，开展HLX319（帕妥珠曲妥珠单抗皮下注射生物类似药）I期临床试验，用于HER2阳性早期或局晚期乳腺癌新辅助治疗；累计研发投入约3387万元。
2026-04-09Subsidiary Henlius' Hanlikang (rituximab injection) received NMPA approval for new indications: combination therapy for previously untreated diffuse large B-cell lymphoma (DLBCL) and for relapsed/refractory DLBCL in patients unfit for stem cell transplant.子公司复宏汉霖的汉利康（利妥昔单抗注射液）获国家药监局批准新增适应症：联合方案用于既往未经治疗的弥漫大B细胞淋巴瘤及不适合移植的复发/难治性弥漫大B细胞淋巴瘤。
2026-04-14Subsidiary Henlius received NMPA approval for Phase I trial of HLX05-N (cetuximab biosimilar, recombinant anti-EGFR chimeric monoclonal antibody) for metastatic colorectal cancer; cumulative R&D investment ~54 million yuan.子公司复宏汉霖获国家药监局批准，开展HLX05-N（西妥昔单抗生物类似药）I期临床试验，用于转移性结直肠癌；累计研发投入约0.54亿元。
2026-04-28Subsidiary Henlius' pertuzumab biosimilar (HLX11, 420mg/14mL) received European Commission marketing authorization for all indications of reference drug Perjeta.子公司复宏汉翰的帕妥珠单抗生物类似药（HLX11，420mg/14mL）获欧盟委员会批准上市，适应症覆盖参照药Perjeta在欧盟所有适应症。
2026-05-10Subsidiary Henlius received US FDA approval to initiate Phase I trial of HLX05-N (cetuximab biosimilar) for metastatic colorectal cancer; cumulative R&D investment ~60 million yuan.控股子公司复宏汉霖获美国FDA批准开展HLX05-N（西妥昔单抗生物类似药）用于转移性结直肠癌的Ⅰ期临床试验；累计研发投入约0.6亿元。
2026-05-21Subsidiary Henlius received NMPA approval for Phase I trial of HLX48 (EGFR/c-MET bispecific ADC) for advanced/metastatic solid tumors; cumulative R&D investment ~66 million yuan.控股子公司复宏汉霖注射用HLX48（靶向EGFR和c-MET的双特异性抗体偶联药物）获国家药监局批准开展Ⅰ期临床试验；累计研发投入约0.66亿元。
2026-05-21Subsidiary Henlius received first global clinical trial approval in Australia for HLX3902 (STEAP1xCD3xCD28 trispecific antibody) for metastatic castration-resistant prostate cancer; cumulative R&D investment ~29 million yuan.控股子公司复宏汉霖HLX3902注射液（STEAP1xCD3xCD28三特异性抗体）获澳大利亚首个全球临床试验许可，用于转移性去势抵抗性前列腺癌；累计研发投入约0.29亿元。
2026-05-21Subsidiary Henlius established a wholly-owned subsidiary, Henlius (Nanjing) Biotechnology Co., Ltd., with registered capital of 50 million yuan.控股子公司复宏汉霖全资设立复星汉霖（南京）生物技术有限公司，注册资本5000万元。
2026-05-29Subsidiary Henlius received NMPA approval for Pertuzumab Injection (Hanbeiyou®), a biosimilar covering all approved indications in China for early and metastatic breast cancer; cumulative R&D investment ~232 million yuan.控股子公司复宏汉霖帕妥珠单抗注射液（汉倍优®）获国家药监局批准，覆盖中国境内所有获批适应症（早期及转移性乳腺癌）；累计研发投入约2.32亿元。
2026-06-02Fosun Pharma's subsidiary Henlius received NMPA approval for its biosimilar Pertuzumab Injection (category 3.3), becoming the 4th domestic manufacturer; the product had sales over 2.8 billion yuan in China in 2025.复星医药子公司复宏汉霖的生物类似药帕妥珠单抗注射液（3.3类）获国家药监局批准，成为国产第四家；该产品2025年中国销售额超28亿元。
2026-06-17Fosun Pharma's subsidiary Henlius received NMPA approval for a Phase I clinical trial of HLX3902, a self-developed trispecific antibody (STEAP1×CD3×CD28), for metastatic castration-resistant prostate cancer and other advanced solid tumors.复星医药子公司复宏汉霖自主研发的三特异性抗体HLX3902（STEAP1×CD3×CD28）获国家药监局批准开展I期临床试验，用于转移性去势抵抗性前列腺癌及其他晚期实体瘤。
2026-06-17Fosun Pharma's subsidiary Henlius passed GMP compliance inspection for its Pertuzumab Injection (Han Bei You) production line at Songjiang base, Shanghai, with design capacity of 12,000L for drug substance; direct investment of 9.32 million yuan.复星医药子公司复宏汉霖位于上海松江生产基地的帕妥珠单抗注射液（汉倍优）生产线通过GMP符合性检查，原液设计产能12000L，直接投入约932万元。
2026-06-17Fosun Pharma's subsidiary Henlius announced Phase II clinical trial approval (via ethics committee and TGA Australia) for HLX43 (PD-L1 ADC) combined with Serplulimab (Han Si Zhuang) for neoadjuvant treatment of non-small cell lung cancer.复星医药子公司复宏汉霖宣布HLX43（PD-L1 ADC）联合斯鲁利单抗（汉斯状）用于非小细胞肺癌新辅助治疗的II期临床试验获伦理委员会批准并通过澳大利亚TGA备案。
2026-07-10NMPA approved Fosun Pharma subsidiary Henlius' IND for HLX37 (anti-PD-L1/VEGF bispecific) combined with chemotherapy or HLX43 (anti-PD-L1 ADC) for advanced/metastatic solid tumors; cumulative R&D investment ~RMB 8.59M.国家药监局批准复星医药子公司复宏汉霖的HLX37（抗PD-L1/VEGF双抗）联合化疗或HLX43（抗PD-L1 ADC）用于晚期/转移性实体瘤的I期临床试验；累计研发投入约859万元。
2026-07-31NMPA approved Henlius' IND for HLX43 (anti-PD-L1 ADC) combined with bevacizumab with or without chemotherapy for advanced/metastatic solid tumors; cumulative R&D investment ~RMB 8.15M.国家药监局批准复宏汉霖的HLX43（抗PD-L1 ADC）联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤的临床试验；累计研发投入约815万元。
2026-08-01Subsidiary Henlius received NMPA approval to initiate a clinical trial for HLX43, a PD-L1-targeting ADC, combined with bevacizumab with or without chemotherapy for advanced/metastatic solid tumors.控股子公司复宏汉霖获国家药监局批准，就靶向PD-L1的抗体偶联药物HLX43联合贝伐珠单抗联合或不联合化疗用于晚期/转移性实体瘤开展临床试验。
2026-08-17Henlius signed a framework agreement with Sandoz AG for overseas licensing of up to 10 biosimilar mAb/ADC products; first 3 products (HLX05-N, HLX16, belimumab biosimilar) with up to $314 million in milestones plus 40% sales share, and $8 million option fee for HLXTE-HAase1001.复宏汉霖与山德士（Sandoz AG）签订合作框架协议，就至多10款单抗/ADC生物类似药开展海外许可合作；首批3款产品（HLX05-N、HLX16、贝利尤单抗生物类似药）可收取至多3.14亿美元里程碑款及40%销售分成，并就HLXTE-HAase1001收取800万美元选择权费。
Share buybacks & capital returns股份回购与资本回报
17 · 2024-03-01 → 2025-07-22
▾
A-share and H-share buyback programs, execution, and related financing.A股和H股回购计划、执行及相关融资。
2024-03-01Chairman Wu Yifang proposed a share buyback of RMB 100-200 million at no more than RMB 30 per share for equity incentives and employee stock ownership plans.董事长吴以芳提议以1亿至2亿元回购股份，回购价不超过30元/股，用于股权激励和员工持股计划。
2024-03-26Board approved share buyback plan of RMB 100-200 million at ≤ RMB 30/share for equity incentives/ESOP, valid from March 26 to September 25, 2024.董事会审议通过回购方案，以1亿至2亿元回购股份，回购价不超过30元/股，用于股权激励/员工持股计划，期限2024年3月26日至9月25日。
2024-04-02Fosun Pharma announced a share buyback plan: up to 200 million yuan (min 100 million yuan) at ≤30 yuan per A-share, over 6 months from March 26, 2024; no shares repurchased as of March 31.复星医药公布回购方案：资金总额不低于1亿元且不超过2亿元，回购价格不超过30元/股，期限6个月；截至3月31日尚未回购。
2024-06-25Fosun Pharma first implemented A-share buyback, repurchasing ~1.16 million shares for ~RMB 25.72 million at avg RMB 22.16/share.复星医药首次实施A股回购，回购约116万股，总金额约2572.26万元，均价22.16元/股。
2024-07-02Fosun Pharma completed A-share repurchases totaling approximately 1.458 million shares (0.0546% of total shares) for about RMB 32.32 million, at prices between RMB 22.03 and 22.32 per share, as of June 30, 2024.截至2024年6月30日，复星医药累计回购A股约145.8万股（占总股本0.0546%），总金额约3232万元，价格区间22.03-22.32元/股。
2024-09-26Fosun Pharma completed its A-share buyback plan, repurchasing 5,677,700 A-shares (0.21% of total shares) for approximately RMB 126.64 million, at an average price of RMB 22.31 per share.复星医药A股回购方案实施完毕，实际回购5,677,700股A股（占总股本0.21%），回购总金额约1.27亿元，均价22.31元/股。
2024-12-27Fosun Pharma repurchased 200,000 H-shares at HKD 14.05 per share, total HKD 2.87 million.复星医药以每股14.05港元回购20万股H股，总金额287万港元。
2024-12-31Fosun Pharma repurchased 180,000 H-shares at up to HKD 14.14 per share, total HKD 2.51 million.复星医药以最高每股14.14港元回购18万股H股，总金额251万港元。
2025-01-22Board approved A-share buyback plan: up to 600 million yuan (min 300 million yuan) at max 30 yuan/share, for convertible bonds or equity incentives; period 6 months.董事会审议通过A股回购方案：资金总额不低于3亿元且不超过6亿元，回购价格上限30元/股，用于可转债转股或股权激励；期限6个月。
2025-01-22Board approved H-share buyback plan: up to 5% of total H-shares (max 27.597 million shares) within 6 months, for cancellation or treasury stock.董事会审议通过H股回购方案：不超过H股总数5%（最多2759.7万股），期限6个月，用于注销或库存股份。
2025-02-04Repurchased 232,000 H-shares on 3 Feb 2025 for HKD 2.95 million; cumulative repurchases of 8.42 million shares represent 1.53% of issued shares under the buyback mandate.2025年2月3日回购23.2万股H股，金额295万港元；累计回购842万股，占回购授权决议通过时已发行股份的1.53%。
2025-03-06Receives a commitment letter from ICBC Shanghai Changning Sub-branch for a loan facility up to 90% of the A-share buyback cap (RMB 300-600 million), supporting the A-share repurchase program.收到中国工商银行上海市长宁支行出具的《承诺函》，承诺贷款额度最高不超过A股回购金额上限（3-6亿元）的90%，为A股回购提供融资支持。
2025-03-26First A-share buyback executed: 812,800 shares repurchased at total cost of RMB 19.99 million (avg. price RMB 24.60/share), as part of the RMB 300-600 million buyback plan approved on Jan 22, 2025.首次实施A股回购：回购812,800股，总金额1999.09万元（均价24.60元/股），作为2025年1月22日批准的3-6亿元回购方案的一部分。
2025-04-02Fosun Pharma announces A-share and H-share buyback progress: as of March 31, 2025, it has repurchased 1.6133 million A-shares for approx. RMB 39.994 million and 1.6555 million H-shares for approx. HKD 22.912 million.复星医药公告A股及H股回购进展：截至2025年3月31日，累计回购161.33万股A股约3999.41万元，回购165.55万股H股约2291.21万港元。
2025-04-08Fosun Pharma announces it will accelerate A-share buybacks within the buyback period to boost investor confidence.复星医药公告将在回购期间内加快实施A股回购，以提振投资者信心。
2025-07-01Company repurchased 532,800 A-shares on June 30 at RMB 25.05-25.09 per share, total ~RMB 13.35M, to be held as treasury shares.公司于6月30日回购53.28万股A股，回购价格区间每股25.05元至25.09元，总金额约1335.42万元，作为库存股持有。
2025-07-22A-share and H-share buyback programs expired; total A-share repurchase ~RMB 348M (14.23M shares), H-share ~HKD 47.84M (3.41M shares).A股及H股回购方案实施期限届满，A股累计回购约3.48亿元（1423万股），H股累计回购约4784万港元（341万股）。
Fund formations & investments基金设立与投资
23 · 2024-03-05 → 2026-08-04
▾
Establishment, filing, and capital changes for various investment funds.各类投资基金的设立、备案及资本变动。
2024-03-05Linhai Fosun Wansheng New Materials Equity Investment Fund completed filing with the Asset Management Association of China (AMAC), filing code SAHP24.临海复星万盛新材料股权投资基金在中国证券投资基金业协会完成备案，备案编码SAHP24。
2024-03-12Subsidiaries Fuxin Shenyao, Fosun Pharma (Shenzhen), Fujian Fund Management, and 7 other investors (including Shenzhen Guidance Fund) set up a target fund with planned total size of RMB 5 billion, focusing on biomedicine, cell and gene therapy in Shenzhen; Fosun entities contribute RMB 1.5 billion total.控股子公司复鑫深耀、复星医药（深圳）、复健基金管理公司与其他7方投资人（含深圳市引导基金）共同出资设立目标基金，计划募集50亿元，聚焦深圳生物医药、细胞和基因领域；复星方合计出资15亿元。
2024-03-13Subsidiary Jinan Fujian Star Future Medical Investment and Ningbo Fuying set up Jinan Star Future Venture Capital Fund, completed AMAC filing; managed by Shanghai Fujian Equity Fund Management.控股子公司济南复健星未来医疗投资及宁波复瀛设立济南星未来创业投资基金，完成备案；由上海复健股权投资基金管理公司管理。
2024-04-02Shenzhen Pengfu Biomedical Industry Private Equity Investment Fund Partnership (L.P.) established with 5 billion yuan capital, involving Fosun Pharma subsidiary and Shenzhen guidance funds.深圳市鹏复生物医药产业私募股权投资基金合伙企业成立，出资额50亿元，复星医药子公司及深圳市引导基金等参与。
2024-04-22Fosun Pharma's two innovation device funds, Anji and Xuzhou, completed filing with the Asset Management Association of China.复星医药参与设立的安吉创新器械基金和徐州创新器械基金完成中国证券投资基金业协会备案。
2024-04-29Fosun Pharma and Shenzhen municipal and district guidance funds signed agreement to establish a 5 billion yuan Shenzhen biomedical industry fund, with Fosun contributing 1.5 billion yuan (30% stake).复星医药与深圳市区两级引导基金签约共同设立50亿元深圳生物医药产业基金，复星现金认缴15亿元（占30%）。
2024-05-31Subsidiary Suzhou Xinglaiwei Fund invested RMB 7.5 million in Puling Bio's A-2 round; Fosun Pharma's total stake in Puling Bio increased to 12.60%.控股企业苏州星未来基金出资750万元参与普灵生物A-2轮融资，复星医药对普灵生物持股增至12.60%。
2024-06-25Fosun Pharma's co-invested Shenzhen Pengfu Biomedical Industry Private Equity Fund completed filing with AMAC, with manager Shanghai Fujian Equity Fund Management.复星医药参与设立的深圳市鹏复生物医药产业私募股权投资基金完成中基协备案，管理人为上海复健股权投资基金管理有限公司。
2024-08-16Fosun Pharma's subsidiary Shanghai Fosun Pingyao Investment Management co-founded Chengdu Jincheng'an Biotech Partnership with capital of RMB 1 million.复星医药旗下上海复星平耀投资管理有限公司参与成立成都金诚安生物技术合伙企业，出资额100万元。
2024-12-11Subsidiary Ningbo Fuying to invest RMB 140.42 million to increase stakes in three funds (Nanjing Fund, Dalian Xingweilai Fund, Suzhou Tianshi Fund) to 66.24%, 51.00%, 64.20% respectively.子公司宁波复瀛拟出资1.4042亿元增持南京基金、大连星未来基金、苏州天使基金份额，持股比例分别升至66.24%、51.00%、64.20%。
2025-04-26Fosun Pharma and affiliates set up Henan Fujian (河南复健) fund with total capital of RMB 10 million, focusing on medical device, life science, and innovative drug investments in central China.复星医药及关联方共同设立河南复健基金，认缴出资总额1000万元，聚焦中原地区医疗器械、生命科学、创新药投资。
2025-05-07Fosun Pharma and its affiliates established Henan Fujian Star Future Health Investment Partnership (limited partnership) with a capital of RMB 10 million, for investment and consulting services.复星医药及其关联方共同出资1000万元成立河南复健星未来健康投资合伙企业（有限合伙），从事投资及咨询服务。
2025-05-16Fosun Pharma and its affiliates established Henan Zhongyuan Medical Science City Star Future Equity Investment Fund (limited partnership) with a capital of RMB 2.5 billion, focusing on innovative drugs, diagnostics, devices and healthcare.复星医药及其关联方共同出资25亿元成立河南中原医学科学城星未来股权投资基金合伙企业，重点投向创新药、诊断检测、器械及医疗健康领域。
2025-06-21Fosun Pharma's subsidiary Suzhou Junming Zhiyuan led the establishment of Henan Star Future Biomedical Fund, which completed filing with AMAC.复星医药控股企业苏州君明致远参与设立的河南星未来生物医药基金完成中基协备案。
2025-07-15Suzhou Angel Fund, in which Fosun holds 62.5% via Ningbo Fuying, approved a proportional capital reduction of RMB 76M, reducing total fund size from RMB 176M to RMB 100M.复星医药通过宁波复瀛持股62.5%的苏州天使基金获准同比例减资7600万元，基金总额从1.76亿元降至1亿元。
2025-08-15Fosun Pharma participated in a reduction of the total subscription size of private equity fund Shanghai Jingxu Rongxu Venture Capital Center by RMB 19.5 million, with its own stake passively increasing to 33.24%.复星医药参与的私募基金上海景旭榕煦创业投资中心总认缴规模缩减1950万元，复星医药持股比例被动增至33.24%。
2025-11-10Fosun Pharma's subsidiary Shanghai Fosun Pharma Industrial participated in establishing Huarun (Chengdu) Medical Industry Equity Investment Fund with RMB 1B capital, alongside Dong'e Ejiao, Boya Bio, etc.复星医药全资子公司上海复星医药产业发展有限公司参与设立华润（成都）医药产业股权投资基金，出资额10亿元，共同出资方包括东阿阿胶、博雅生物等。
2026-01-14Fosun Pharma's subsidiary participated in the establishment of Zhonghui Fuhong (Tianjin) Equity Investment Fund Partnership (L.P.) with a capital of 547 million yuan, alongside Zhonghui Life Insurance and Hongyi Private Equity.复星医药全资子公司参与设立中汇复弘（天津）股权投资基金合伙企业（有限合伙），出资额5.47亿元，合伙人包括中汇人寿保险和弘毅私募。
2026-04-01Fosun Pharma established Tianjin Fosun Haihe Medical Health Industry Phase II Venture Capital Fund (LP) with a capital of 1 billion yuan, involving Tianjin Haihe Industrial Fund and Fosun Pharma's subsidiary Suzhou Junming Zhiyuan.复星医药参与设立天津复星海河医疗健康产业二期创业投资基金（有限合伙），出资额10亿元，合伙人包括天津市海河产业基金及复星医药旗下苏州君明致远。
2026-05-28Subsidiary Suzhou Junming and 7 other parties established Hangzhou Fund with planned total size of 1 billion yuan; Suzhou Junming commits 278 million yuan.控股企业苏州君明与其他7方共同设立杭州基金，计划募集规模10亿元；苏州君明认缴出资2.78亿元。
2026-06-09Fosun Pharma and partners established a new medical investment partnership in Jinan, 'Jinan Fuhuixing Future Medical Investment Management Partnership', with a capital contribution of 75.01 million yuan.复星医药与合作伙伴在济南成立新医疗投资合伙企业“济南市复惠星未来医疗投资管理合伙企业”，出资额7501万元。
2026-07-30Fosun Pharma's subsidiary as LP completed filing of Tianjin Fosun Haihe Medical Health Industry Phase II Venture Capital Fund (and parallel Hangzhou fund) with AMAC; custodian is Bank of Hangzhou.复星医药控股子公司作为LP参与的天津复星海河医疗健康产业二期创业投资基金（及杭州平行基金）完成中国证券投资基金业协会备案；托管人为杭州银行。
2026-08-04Two industry funds co-established by Fosun Pharma, Tianjin Fosun Haihe Medical Health Industry Phase II Fund and Hangzhou Fuyao Xingqi Achievement Transformation Fund, completed filing with AMAC.复星医药参与设立的天津复星海河医疗健康产业二期基金及杭州复曜星启成果转化基金均已完成中基协备案。
Controlling shareholder pledges控股股东质押
20 · 2024-03-20 → 2026-08-07
▾
A continuous series of share pledges and releases by controlling shareholder Fosun High Technology.控股股东复星高科技持续进行的一系列股份质押与解除。
2024-03-20Controlling shareholder Fosun High Technology released pledge of 50 million A-shares (1.87% of total shares) on March 19, 2024; remaining pledged shares 658 million (24.62% of total).控股股东复星高科技于2024年3月19日解除质押5000万股A股（占总股本1.87%）；剩余质押6.58亿股（占总股本24.62%）。
2024-05-27Controlling shareholder Fosun High Technology pledged 90 million shares (3.37% of total) and released 40 million shares; total pledged shares reached 73.42% of its holdings.控股股东复星高科技质押9000万股（占总股本3.37%）并解除质押4000万股，累计质押占其持股73.42%。
2024-10-22Fosun Pharma's controlling shareholder Fosun High Technology pledged 68.5 million A-shares for debt repayment; total pledged shares reached 646.4 million, representing 24.20% of total issued shares and 66.79% of the shareholder's holdings.复星医药控股股东复星高科技质押6850万股A股用于偿还债务；累计质押股份达6.464亿股，占已发行股份总数的24.20%，占其所持股份的66.79%。
2024-11-08Fosun Pharma's controlling shareholder Fosun High Technology pledged 7.4 million A-shares to ICBC Shanghai Changning Sub-branch, increasing cumulative pledged shares to 653.8 million (24.47% of total shares).复星医药控股股东复星高科向工商银行上海市长宁支行质押740万股A股，累计质押股份增至6.538亿股（占总股本24.47%）。
2024-11-27Fosun Pharma's controlling shareholder Fosun High Technology released a pledge on 120 million A-shares, reducing cumulative pledged shares to 533.8 million (19.98% of total shares).复星医药控股股东复星高科解除1.2亿股A股质押，累计质押股份降至5.338亿股（占总股本19.98%）。
2024-12-23Controlling shareholder Fosun High Technology pledged 198 million A-shares (7.41% of total) to ICBC Shanghai Changning sub-branch for debt repayment.控股股东复星高科技向工商银行上海市长宁支行质押1.98亿股A股（占总股本7.41%），用于偿还债务。
2025-02-13Controlling shareholder Fosun High Technology pledged 119.5 million shares (12.43% of its holding) and released 124 million shares; after transaction, pledged shares account for 73.08% of its holding.控股股东复星高科技质押1.195亿股（占其持股12.43%）并解除质押1.24亿股；质押后累计质押股份占其持股的73.08%。
2025-02-20Controlling shareholder Fosun High Technology released pledge on 59 million shares (6.14% of its holding); remaining pledged shares account for 66.99% of its holding.控股股东复星高科技解除质押5900万股（占其持股6.14%）；剩余质押股份占其持股的66.99%。
2025-02-25Controlling shareholder Fosun High Technology pledged 30 million shares (1.12% of total shares) for debt repayment; cumulative pledged shares reach 70.55% of its holding.控股股东复星高科技质押3000万股（占总股本1.12%）用于偿还债务；累计质押股份占其持股的70.55%。
2025-03-27Controlling shareholder Fosun High Technology pledges 30 million A-shares (1.12% of total shares) to ICBC Shanghai Changning Sub-branch for debt repayment; cumulative pledges reach 73.19% of its holdings.控股股东复星高科技质押3000万股A股（占总股本1.12%）给工商银行上海市长宁支行用于偿还债务；累计质押占其持股的73.19%。
2025-04-03Controlling shareholder Fosun High Technology partially releases pledge of A-shares; remaining pledged shares account for 70.40% of its holdings.控股股东复星高科技部分解除A股质押；剩余质押股份占其持股的70.40%。
2025-05-22Controlling shareholder Fosun High Technology pledged 30 million A-shares (1.12% of total shares) to ICBC Shanghai Changning Sub-branch for debt repayment; cumulative pledged shares reached 73.50% of its holdings.控股股东复星高科技质押3000万股A股（占总股本1.12%）给工商银行长宁支行用于偿还债务；累计质押股份占其持股的73.50%。
2025-06-17Controlling shareholder Fosun High Technology pledged 21 million shares and released 47 million shares; total pledged shares reached 685.3 million, 71.28% of its holdings.控股股东复星高科技质押2100万股、解除质押4700万股；累计质押6.853亿股，占其持股的71.28%。
2025-08-14Fosun Pharma's controlling shareholder Fosun High Technology pledged 49 million A-shares (1.83% of total) to ICBC Shanghai Changning Sub-branch for debt repayment, and simultaneously released a pledge on 121.625 million shares.复星医药控股股东复星高科技质押4900万股A股（占总股本1.83%）给工商银行上海长宁支行用于偿还债务，同时解除1.21625亿股质押。
2025-11-07Controlling shareholder Fosun High Technology pledged 20M shares and released 85.75M shares; after changes, cumulative pledged shares 546.925M (20.48% of total shares, 56.51% of its holdings).控股股东复星高科技质押2000万股、解除质押8575万股；变动后累计质押5.46925亿股（占总股本20.48%，占其持股56.51%）。
2026-01-22Fosun Pharma's controlling shareholder Fosun High Technology pledged 32 million A-shares to ICBC Shanghai Changning Sub-branch for debt repayment, while releasing 102.65 million shares from pledge; net pledged shares reduced to 476 million, or 17.84% of total shares.复星医药控股股东复星高科技将3200万股A股质押给工商银行上海市长宁支行用于偿还债务，同时解除质押1.0265亿股；质押余额降至4.76亿股，占总股本17.84%。
2026-04-15Controlling shareholder Fosun High Technology pledged 69 million shares (2.58% of total shares) for debt repayment; cumulative pledged shares reached 545.275 million (20.42% of total shares, 56.34% of its holdings).控股股东复星高科技质押6900万股（占总股本2.58%）用于偿还债务；累计质押股份达5.45275亿股（占总股本20.42%，占其持股56.34%）。
2026-07-15Controlling shareholder Fosun High Technology pledged 47M shares (1.76% of total) for debt repayment; cumulative pledges reached 61.6% of its holdings (22.18% of total).控股股东复星高科技质押4700万股（占总股本1.76%）用于偿还债务；累计质押股份占其持股61.6%（占总股本22.18%）。
2026-07-22Controlling shareholder Fosun High Technology released pledge on 69M shares (2.58% of total); remaining pledged shares reduced to 523.275M (19.60% of total).控股股东复星高科技解除6900万股（占总股本2.58%）的质押；剩余质押股份降至5.23亿股（占总股本19.60%）。
2026-08-07Controlling shareholder Fosun High Technology released a pledge on 157 million A-shares (5.88% of total share capital) on Aug 6; remaining pledged shares reduced to 13.72% of total share capital, with possible future pledges.控股股东复星高科技于8月6日解除质押1.57亿股A股（占总股本5.88%）；剩余质押股份占总股本比例降至13.72%，并存在后续质押计划。
Vaccine pipeline & manufacturing疫苗管线与生产
14 · 2024-03-20 → 2026-06-26
▾
Development, approval, and manufacturing base for various vaccines, including rabies, pneumococcal, and influenza.狂犬病、肺炎球菌和流感等多种疫苗的开发、获批及生产基地。
2024-03-20Subsidiary Fosun Yalifeng (Dalian) passed GMP inspection for rabies vaccine bulk drug substance and packaging lines; self-developed freeze-dried human rabies vaccine (Vero cell) received NMPA marketing approval.控股子公司复星雅立峰（大连）狂苗原液车间及分包装车间通过GMP符合性检查；自主研发的冻干人用狂犬病疫苗（Vero细胞）获国家药监局批准上市。
2024-04-29Fosun Pharma's self-developed freeze-dried human rabies vaccine (Vero cell) and F-i6000 fully automatic chemiluminescence immunoassay analyzer approved for marketing in Q1 2024.复星医药自主研发的冻干人用狂犬病疫苗（Vero细胞）和F-i6000全自动化学发光免疫分析仪于2024年一季度获批上市。
2024-06-12Fosun Pharma's subsidiary Yalifeng's freeze-dried rabies vaccine (Vero cell) was approved in March 2024 but not yet marketed; currently in production and batch release approval stage.复星医药子公司雅立峰的冻干人用狂犬病疫苗（Vero细胞）于2024年3月获批，但尚未上市销售，目前处于生产和批签发报批阶段。
2024-08-22Fosun Pharma's subsidiary Futu Anteris (Chengdu) obtained clinical trial approval for a 23-valent pneumococcal polysaccharide vaccine (category 3.3).复星医药旗下复星安特金（成都）的23价肺炎球菌多糖疫苗（注册分类3.3）获临床试验批准。
2024-08-29Fosun Pharma launched the innovative vaccine headquarters and industrialization base project in Chengdu Tianfu International Bio-Town, covering 65,656 sqm, focusing on pneumonia, meningitis, and recombinant protein vaccines.复星医药在成都天府国际生物城启动创新疫苗总部及产业化基地项目，占地65656平方米，重点建设肺炎、流脑、重组蛋白疫苗等产品。
2024-10-11Fosun Pharma confirmed it is actively advancing the registration application for its quadrivalent influenza vaccine, which is currently under review by the National Medical Products Administration.复星医药确认，正在积极推进四价流感疫苗的上市注册申请工作，目前该疫苗正处于国家药监局的审评审批阶段。
2025-03-04Subsidiary Fosun Antigen receives clinical trial approval for a 24-valent pneumococcal polysaccharide conjugate vaccine (self-developed, Class 1.4 preventive biologic); Phase I trial to be conducted in China; cumulative R&D investment approx. RMB 44 million.控股子公司复星安特金获24价肺炎球菌多糖结合疫苗（自主研发，预防用生物制品1.4类）临床试验批准，拟在中国境内开展I期临床试验，累计研发投入约0.44亿元。
2025-10-28Fosun Pharma plans to spin off vaccine subsidiary Fosun Ante Jin (复星安特金) for listing on HKEX.复星医药拟筹划分拆疫苗子公司复星安特金于香港联交所上市。
2026-01-22Fosun Pharma announced plans to spin off its subsidiary Fosun Antengene (Chengdu) Biopharmaceutical Co., Ltd. for listing on the Main Board of the Hong Kong Stock Exchange, with Fosun Pharma retaining control.复星医药公告拟分拆所属子公司复星安特金（成都）生物制药股份有限公司至香港联交所主板上市，分拆后复星医药仍维持控制权。
2026-02-26Fosun Pharma announced a plan to spin off its subsidiary Fosun Antigen (Chengdu) for a separate listing on the Hong Kong Stock Exchange main board.复星医药宣布拟分拆子公司复星安特金（成都）至香港联交所主板独立上市。
2026-02-27Fosun Pharma's shareholders' meetings approved the overall spin-off plan for Fosun Antigen, but the A-share class meeting rejected the proposal to provide assured quotas only to H-share holders.复星医药股东会审议通过复星安特金分拆上市整体方案，但A股类别股东会否决了仅向H股股东提供保证配额的议案。
2026-02-27Fosun Pharma's independent financial advisor CICC issued a special verification opinion, finding no direct evidence of insider trading related to the Fosun Antigen spin-off.复星医药独立财务顾问中金公司出具专项核查意见，未发现与复星安特金分拆相关的内幕交易直接证据。
2026-06-15Fosun Pharma's subsidiary Fosun Antigen (Fosun Antekin) completed a 968 million yuan capital increase, issuing 11.495 million shares at 84.21 yuan each to 4 investors (including Huarun, Chengdu Guosheng, Shanghai Jingxu); Fosun Pharma Industrial invested 550 million yuan, post-investment stake 68.47%.复星医药子公司复星安特金完成9.68亿元增资扩股，以每股84.21元向4家投资人发行1149.5万股（包括华润、成都国生、上海景旭）；复星医药产业出资5.5亿元，增资后持股68.47%。
2026-06-26Fosun Pharma's subsidiary Fosun Antigen (Fosun Antekin) submitted a listing application to the Hong Kong Stock Exchange for H-share IPO, with CICC and Fosun International Capital as joint sponsors; initial issue size up to 25% of enlarged share capital plus 15% over-allotment.复星医药子公司复星安特金向港交所提交H股上市申请，中金公司和复星国际资本为联席保荐人；初始发行规模不超过扩大后总股本的25%并附15%超额配售权。
Intuitive Fosun (da Vinci & Ion) expansion直观复星（达芬奇与Ion）扩张
9 · 2024-03-21 → 2025-03-21
▾
Approvals, new headquarters, and commercial progress for the surgical robotics joint venture.手术机器人合资企业的获批、新总部及商业化进展。
2024-03-21Joint venture Intuitive Fosun's Ion bronchoscopic navigation system received NMPA approval for marketing in China; system already used in US/UK with 500+ installations and 85,000+ procedures globally.联营公司直观复星的Ion支气管导航操作控制系统获国家药监局批准上市；该系统已在美英上市，全球装机500多台，手术量超8.5万例。
2024-04-15Intuitive Fosun's new headquarters in Shanghai Pudong expected to be completed in 2024, becoming the second global R&D and manufacturing base for da Vinci surgical robots after Silicon Valley; Ion bronchial navigation system approved by NMPA in March 2024.直观复星上海浦东新总部预计2024年建成，成为达芬奇手术机器人继硅谷后全球第二个研发制造基地；Ion支气管导航系统2024年3月获国家药监局批准。
2024-06-13Fosun Pharma and Intuitive Surgical's joint venture, Intuitive Fosun, officially launched its headquarters industrial base in Shanghai, with total investment of ~RMB 7 billion, the largest R&D, production, and training base for surgical robots in Asia-Pacific.复星医药与直观医疗的合资企业直观复星在上海正式启用总部产业基地，总投资约7亿元，为亚太地区最大的手术机器人研发、生产和培训一体化基地。
2024-09-05Joint venture Intuitive Fosun's domestic Da Vinci Xi surgical system and Ion bronchial navigation system were approved by NMPA; its Shanghai HQ became the second global R&D and manufacturing base after Silicon Valley.联营公司直观复星的国产达芬奇第四代手术系统及Ion支气管导航操作控制系统获国家药监局批准；上海总部产业基地落成启用，成为继硅谷后全球第二个研发与制造基地。
2024-11-06At the 7th China International Import Expo, Fosun Pharma showcased the Ion bronchoscopy robot, which transitioned from 'exhibit' to 'commercial product' in 2024.在第七届中国国际进口博览会上，复星医药展出了Ion支气管镜机器人，该产品于2024年实现从“展品”到“商品”的转变。
2024-11-07Intuitive Fosun and Siemens Healthineers released a 'bronchoscopy robot precision diagnosis and treatment solution', integrating Ion bronchoscopy robot with Cios Spin CBCT system for real-time target updates during biopsy.直观复星与西门子医疗发布“支气管镜机器人精准诊疗解决方案”，将Ion支气管镜机器人与Cios Spin CBCT系统集成，在活检过程中实现靶点实时更新。
2025-01-02Intuitive Fosun headquarters base in Zhangjiang Shanghai completed and put into use; total investment ~700 million yuan, largest R&D/production/training base of Intuitive in Asia-Pacific.直观复星总部产业基地于上海张江落成启用，总投资约7亿元，是直观医疗在亚太地区最大的研发、生产和培训一体化基地。
2025-02-19Established Intuitive Fosun Medical Devices (Hainan) Co., Ltd. with registered capital of RMB 20 million, wholly owned by Intuitive Fosun Medical Technology (Shanghai), for medical device sales and marketing.成立直观复星医疗器械（海南）有限公司，注册资本2000万元，由直观复星医疗器械技术（上海）全资持股，从事医疗器械销售及营销策划。
2025-03-21Establishes Guanxing Medical Devices (Beijing) Co., Ltd., a joint venture with Intuitive Surgical (via Intuitive Fosun), with registered capital of RMB 20 million, for medical device sales and trading.与直观复星（Intuitive Surgical合资）共同投资成立观星医疗器械（北京）有限公司，注册资本2000万元，从事医疗器械销售及贸易。
Financial results & dividends财务业绩与分红
18 · 2024-03-26 → 2026-08-25
▾
Quarterly and annual financial results, dividend announcements, and related shareholder returns.季度和年度财务业绩、分红公告及相关股东回报。
2024-03-26FY2023 revenue RMB 41.4 billion, down 5.81% YoY; net profit attributable to shareholders RMB 2.386 billion, down 36.04% YoY; proposed dividend RMB 0.27 per 10 shares. Ex-COVID products, revenue grew ~12.43% YoY.2023年营收414亿元，同比下降5.81%；归母净利润23.86亿元，同比下降36.04%；拟每10股派发现金红利2.70元。不含新冠相关产品，营收同比增长约12.43%。
2024-04-01Fosun Pharma 2023 annual report: 6 innovative drugs with 8 indications approved; 50 products with sales over 100 million yuan; COVID-related business still incurring expenses.复星医药2023年报：6个创新药的8项适应症获批；销售额过亿产品达50个；新冠相关业务仍有费用发生。
2024-04-29Fosun Pharma Q1 2024 results: revenue 10.157 billion yuan (-6.56% YoY), net profit 610 million yuan (-38.22% YoY), mainly due to sharp decline in COVID-related product sales.复星医药2024年一季度业绩：营收101.57亿元（同比-6.56%），净利润6.1亿元（同比-38.22%），主要因新冠相关产品收入大幅下降。
2024-07-29Fosun Pharma announced 2023 annual A-share cash dividend of RMB 0.27 per share (tax-exclusive), with record date August 5, 2024 and ex-dividend date August 6, 2024.复星医药宣布2023年度A股每股派发现金红利0.27元（税前），股权登记日2024年8月5日，除权除息日2024年8月6日。
2024-08-27Fosun Pharma reported H1 2024 revenue of RMB 20.463 billion, down 4.36% YoY; net profit of RMB 1.225 billion, down 31.09% YoY; ex-COVID products revenue grew 5.31%.复星医药2024年上半年营收204.63亿元，同比下降4.36%；净利润12.25亿元，同比下降31.09%；不含新冠产品营收同比增长5.31%。
2024-10-29Fosun Pharma reported Q3 2024 results: 9M revenue 30.91 billion yuan (+0.7% YoY); net profit 2.01 billion yuan (-11.9% YoY); Q3 revenue 10.45 billion yuan (+12.3% YoY); Q3 net profit 786 million yuan (+55.4% YoY). Core non-GAAP net profit for 9M was 1.84 billion yuan (+24.6% YoY).复星医药公布2024年三季度业绩：前三季度营收309.12亿元（同比+0.7%）；净利润20.11亿元（同比-11.9%）；第三季度营收104.49亿元（同比+12.3%）；第三季度净利润7.86亿元（同比+55.4%）。前三季度扣非净利润18.36亿元（同比+24.6%）。
2025-03-25FY2024 results: revenue RMB 41.067 billion (-0.80% YoY); net profit attributable to shareholders RMB 2.77 billion (+16.08% YoY); proposes cash dividend of RMB 3.20 per 10 shares. Core innovative products (serplulimab, axicabtagene ciloleucel, etc.) achieved rapid growth.2024年年报：营业收入410.67亿元（同比-0.80%）；归母净利润27.7亿元（同比+16.08%）；拟每10股派发现金红利3.20元。核心创新产品（斯鲁利单抗、阿基仑赛等）实现较快增长。
2025-04-01Fosun Pharma's 2024 annual report: revenue RMB 41.067 billion, down 0.80% YoY; net profit RMB 2.77 billion, up 16.08% YoY; operating cash flow RMB 4.477 billion, up 31.13% YoY.复星医药2024年年报：营业收入410.67亿元，同比下降0.80%；净利润27.70亿元，同比增长16.08%；经营现金流44.77亿元，同比增长31.13%。
2025-04-29Fosun Pharma reports Q1 2025 results: revenue RMB 9.42 billion, down 7.26% YoY; net profit RMB 765 million, up 25.42% YoY; operating cash flow RMB 1.056 billion, up 15.08% YoY.复星医药2025年一季报：营业收入94.20亿元，同比下降7.26%；净利润7.65亿元，同比增长25.42%；经营现金流10.56亿元，同比增长15.08%。
2025-07-25Company announced 2024 profit distribution: RMB 3.20 per 10 A-shares (pre-tax), total cash dividend ~RMB 672M based on 2.099B eligible A-shares.公司公布2024年度利润分配预案：每10股派发现金红利3.20元（税前），以可参与分配的A股约20.99亿股计算，共计派发现金红利约6.72亿元。
2025-08-26Fosun Pharma reported H1 2025 results: revenue RMB 19.514 billion (-4.63% YoY), net profit RMB 1.702 billion (+38.96% YoY), innovative drug revenue over RMB 4.3 billion (+14.26% YoY).复星医药发布2025年半年报：营收195.14亿元（同比-4.63%），净利润17.02亿元（同比+38.96%），创新药品收入超43亿元（同比+14.26%）。
2025-09-04Fosun Pharma 2025 interim report: net profit attributable to shareholders up 38.96% YoY to RMB 1.702 billion, mainly due to gain from disposal of United Family Healthcare residual equity and other non-core assets (RMB 9.491 billion); core business net profit (excl. non-recurring) was RMB 961 million, down 23.39% YoY.复星医药2025年半年报：归母净利润同比增38.96%至17.02亿元，主要因出售和睦家剩余权益及其他非核心资产收益（94.91亿元）；扣非净利润9.61亿元，同比减少23.39%。
2025-10-28Fosun Pharma reported Q3 2025 revenue of RMB 9.879B (-5.46% YoY), net profit RMB 821M (+4.52% YoY); 9M revenue RMB 29.393B (-4.91%), net profit RMB 2.523B (+25.5%).复星医药2025年第三季度营收98.79亿元（同比-5.46%），净利润8.21亿元（同比+4.52%）；前三季度营收293.93亿元（同比-4.91%），净利润25.23亿元（同比+25.5%）。
2025-11-03Fosun Pharma reported Q3 2025 results: 9M revenue RMB 29.393B, net profit RMB 2.523B (+25.5% YoY); innovative drug revenue exceeded RMB 6.7B (+18.09% YoY); Q3 R&D expense RMB 1.013B (+28.81% YoY).复星医药公布2025年三季报：前三季度营收293.93亿元，归母净利润25.23亿元（同比+25.5%）；创新药品收入超67亿元（同比+18.09%）；三季度研发费用10.13亿元（同比+28.81%）。
2026-03-24Fosun Pharma reported 2025 annual results: revenue RMB 41.662 billion (+1.45% YoY), net profit attributable to shareholders RMB 3.371 billion (+21.69% YoY), innovative drug revenue RMB 9.893 billion (+29.59% YoY), overseas revenue RMB 12.977 billion (+14.87% YoY). Proposed cash dividend of RMB 3.90 per 10 shares.复星医药发布2025年年报：营业收入416.62亿元（同比+1.45%），归母净利润33.71亿元（同比+21.69%），创新药品收入98.93亿元（同比+29.59%），境外收入129.77亿元（同比+14.87%）。拟每10股派发现金红利3.90元。
2026-04-28Fosun Pharma reported Q1 2026 results: revenue 10.073 billion yuan (+6.93% YoY), net profit 871 million yuan (+13.87% YoY), R&D expense 897 million yuan (+1.59 billion YoY); 4 innovative drug NDA submissions and 14 clinical trial approvals in the quarter.复星医药发布2026年一季报：营业收入100.73亿元（同比+6.93%），归母净利润8.71亿元（同比+13.87%），研发费用8.97亿元（同比增加1.59亿元）；季度内4款创新药上市申请获受理，14项临床试验获批。
2026-07-16Fosun Pharma announced 2025 annual dividend of RMB 0.39 per share (pre-tax), totaling ~RMB 1.029B; record date July 24, ex-dividend July 27, 2026.复星医药公布2025年度权益分派，每股派发现金红利0.39元（税前），合计约10.29亿元；股权登记日7月24日，除权除息日7月27日。
2026-08-25H1 2026 results: revenue RMB 20.442 billion (+4.75% YoY), net profit attributable to shareholders RMB 1.721 billion (+1.15%), non-GAAP net profit RMB 1.144 billion (+19.09%), operating cash flow RMB 2.424 billion (+13.59%), R&D investment RMB 3.247 billion (+25.66%).2026年上半年业绩：营业收入204.42亿元（同比增长4.75%），归母净利润17.21亿元（同比增长1.15%），扣非净利润11.44亿元（同比增长19.09%），经营现金流24.24亿元（同比增长13.59%），研发投入32.47亿元（同比增长25.66%）。
Asset divestitures & stake sales资产剥离与股权出售
15 · 2024-04-15 → 2026-04-23
▾
Sales of stakes in various companies, including Gland Pharma, United Family, and others.出售多家公司的股权，包括Gland Pharma、和睦家等。
2024-04-15BNP Paribas acquired Fosun Group's 9% stake in Belgian insurer Ageas for an estimated 730 million euros.法国巴黎银行以约7.3亿欧元收购复星集团持有的比利时保险公司Ageas 9%权益。
2024-06-19Fosun Pharma sold 6.01% stake in Gland Pharma via block trade at avg INR 1,771.81/share, total ~USD 211 million; post-trade holding ~51.83%, maintaining control.复星医药通过大宗交易出售Gland Pharma 6.01%股权，均价1771.81印度卢比/股，总对价约2.11亿美元；交易后持股约51.83%，仍保持控股权。
2024-06-28Fosun Pharma plans to reduce its stake in Shanhe Medical by up to 1% (2.326 million shares) via block trade from July 22 to Oct 20, 2024, citing operational needs.复星医药计划于2024年7月22日至10月20日期间通过集中竞价减持山河药辅不超过1%股份（232.6万股），原因为经营需要。
2024-08-27Fosun Pharma completed or signed asset disposals totaling over RMB 2 billion in 2024, including sale of 6.01% stake in Gland Pharma for about $211 million.复星医药2024年已完成及已签约待收回的资产处置总额超20亿元，包括出售Gland Pharma 6.01%股权，对价约2.11亿美元。
2024-09-05Fosun Tourism Group sold 100% of Thomas Cook Tourism (UK) to ESKY.PL S.A. for a maximum total consideration of GBP 30 million.复星旅游文化出售Thomas Cook Tourism (UK) Company Limited 100%股权予ESKY.PL S.A.，最高总代价3000万英镑。
2025-02-23Fosun Pharma Industrial plans to reduce its stake in Shanhe Yaofu by up to 3% (6.978 million shares) via block and centralized trading from 18 Mar to 15 Jun 2025.复星医药产业计划于2025年3月18日至6月15日以集中竞价和大宗交易方式减持山河药辅不超过697.8万股（占总股本3%）。
2025-03-13Subsidiary Fosun Industrial agrees to sell its entire 6.6% stake (9.4 million shares) in the entity holding 'United Family' hospitals and clinics to Calcite Gem (Warburg Pincus) for USD 124.08 million; expected post-tax gain of approx. RMB 650 million.控股子公司复星实业拟以1.24亿美元向Calcite Gem（华平投资）转让其持有的运营“和睦家”医院和诊所的标的公司全部6.6%股权（940万股），预计贡献税后收益约6.5亿元。
2025-05-01Fosun Pharma reported 2025 Q1 revenue of RMB 9.42 billion, down 7.26% YoY; net profit attributable to parent of RMB 765 million, up 25.42% YoY, partly due to gain from sale of Unicorn II Holdings (main asset: United Family Hospital).复星医药公布2025年一季度营收94.2亿元，同比下降7.26%；归母净利润7.65亿元，同比增长25.42%，部分得益于出售Unicorn II Holdings（主要资产为和睦家医院）的收益。
2025-05-07Fosun Pharma's shareholder Fosun Weiyin plans to reduce its stake in Huayang Intelligent by up to 5% (2.85 million shares) via block and centralized bidding from May 29 to Aug 28, 2025.复星医药股东复星惟盈计划在2025年5月29日至8月28日期间，通过集中竞价和大宗交易减持华阳智能不超过285万股（占总股本5%）。
2025-06-16Fosun Pharma completed减持 of 2.2828 million shares in Shanhe Pharmaceutical (300452.SZ), representing 0.98% of its total shares.复星医药完成减持山河药辅228.28万股，占其总股本的0.98%。
2025-09-01Fosun International subsidiary SIHL signed a settlement deed with Cainiao Smart Logistics to cancel all Cainiao shares at USD 0.62 per share, total consideration USD 349.8 million, avoiding litigation under Cayman Companies Law.复星国际附属公司SIHL与菜鸟智慧物流签订和解契据，以每股0.62美元注销全部菜鸟股份，总对价3.498亿美元，避免开曼公司法诉讼。
2025-10-31Shareholder Fosun Pharma Industrial plans to sell up to 3% stake in Shanhe Yaofu (山河药辅) via block and open market trades (Nov 24, 2025 - Feb 21, 2026).股东复星医药产业计划减持山河药辅不超过3%股份，期间为2025年11月24日至2026年2月21日。
2025-11-10Fosun Weiying (a Fosun affiliate) plans to reduce its stake in Huayang Intelligent by up to 5% (2,854,175 shares) via centralized竞价 and block trades from Dec 2, 2025 to Mar 1, 2026.Fosun Weiying (a Fosun affiliate) plans to reduce its stake in Huayang Intelligent by up to 5% (2,854,175 shares) via centralized竞价 and block trades from Dec 2, 2025 to Mar 1, 2026.
2026-03-24Subsidiary Fosun Pharma Industrial plans to transfer 100% equity of Shanghai Clonbiotech to a special-purpose fund; fund has completed registration with initial capital contribution of RMB 30 million; signing deadline extended to Sep 30, 2026.控股子公司复星医药产业拟向专项基金转让上海克隆生物高技术有限公司100%股权；专项基金已完成注册，首期实缴出资3000万元；协议签署截止日延至2026年9月30日。
2026-04-23Fosun Pharma's subsidiary Fosun Medical Technology agreed to sell 100% equity of Huaiyin Medical to Mai Kewei Medical; a special fund Zhonghui Fuhong (Tianjin) Equity Investment Fund was established for the sale, managed by Hony Capital.复星医药子公司复星诊疗科技拟将淮阴医疗器械100%股权出售给迈科唯医疗；为此设立专项基金中汇复弘（天津）股权投资基金，由弘毅私募管理。
FCN-159 (Fumaining/Luwometinib) developmentFCN-159（夫美宁/芦沃美替尼）开发
11 · 2024-04-17 → 2026-06-15
▾
Development and approval of the MEK1/2 inhibitor FCN-159 across multiple indications.MEK1/2抑制剂FCN-159在多个适应症上的开发与获批。
2024-04-17Fosun Pharma's FCN-159 (MEK1/2 inhibitor) proposed for priority review by CDE for adult dendritic cell and histiocytic tumors.复星医药FCN-159片（MEK1/2抑制剂）拟纳入优先审评，用于成人树突状细胞和组织细胞肿瘤。
2024-05-24Subsidiary Fosun Pharma Industrial received NMPA acceptance of the marketing application for self-developed Fumetinib (FCN-159, MEK1/2 inhibitor) for adult dendritic cell and histiocytic tumors, previously granted priority review.控股子公司复星医药产业自主研发的复迈替尼片（FCN-159，MEK1/2抑制剂）用于成人树突状细胞和组织细胞肿瘤的上市申请获国家药监局受理，此前已纳入优先审评。
2024-06-06Fosun Pharma's self-developed Fumetini Tablets (FCN-159), a MEK1/2 inhibitor for pediatric NF1-related PN, received NMPA registration acceptance and priority review; cumulative R&D investment ~RMB 499 million.复星医药自主研发的复迈替尼片（FCN-159，MEK1/2抑制剂）用于儿童NF1相关丛状神经纤维瘤的药品注册申请获国家药监局受理并纳入优先审评；累计研发投入约4.99亿元。
2025-05-12FCN-159 (MEK1/2 inhibitor) for pediatric Langerhans cell histiocytosis was granted Breakthrough Therapy designation by China's NMPA; cumulative R&D investment reached ~RMB 598 million.FCN-159（MEK1/2抑制剂）用于儿童朗格汉斯组织细胞增生症获国家药监局突破性治疗药物程序认定；累计研发投入约5.98亿元。
2025-05-29NMPA approved the marketing of Luwometinib tablets (Fumaining, FCN-159), a MEK1/2 inhibitor, for adult LCH/histiocytic tumors and pediatric NF1-related plexiform neurofibromas; cumulative R&D ~RMB 598 million.国家药监局批准芦沃美替尼片（复迈宁，FCN-159）上市，用于成人朗格汉斯细胞组织细胞增生症/组织细胞肿瘤及儿童I型神经纤维瘤病相关丛状神经纤维瘤；累计研发投入约5.98亿元。
2025-06-16Fosun Pharma's self-developed Class 1 new drug Luwometinib Tablets (Fumaining) completed first batch shipment for adult Langerhans cell histiocytosis and pediatric neurofibromatosis type I.复星医药自主研发的1类新药芦沃美替尼片（复迈宁®）完成首批发货，用于成人朗格汉斯细胞组织细胞增生症及儿童青少年I型神经纤维瘤病。
2025-07-09Subsidiary Shanghai Fosun Pharmaceutical Industrial Development initiated Phase III trial in China for Fumaining (luwomitinib, MEK1/2 inhibitor) in pediatric low-grade glioma; cumulative R&D investment ~RMB 607M.子公司上海复星医药产业发展有限公司就复迈宁（芦沃美替尼片，MEK1/2抑制剂）用于治疗儿童低级别脑胶质瘤在中国启动Ⅲ期临床试验，累计研发投入约6.07亿元。
2025-11-21Subsidiary Fosun Pharma Industrial's Fumaining® (lumefantrine tablets, MEK1/2 inhibitor) for LCH in children aged ≥2 years was accepted by NMPA and granted priority review.控股子公司复星医药产业的复迈宁®（芦沃美替尼片，MEK1/2抑制剂）用于2岁及以上朗格汉斯细胞组织细胞增生症儿童患者的注册申请获国家药监局受理并纳入优先审评。
2026-01-16Fosun Pharma's drug Luvometinib (芦沃美替尼片) was proposed for priority review by CDE for treating symptomatic, inoperable plexiform neurofibroma in adults with neurofibromatosis type 1.复星医药芦沃美替尼片拟纳入优先审评品种，适应症为伴有症状、无法手术的丛状神经纤维瘤的Ⅰ型神经纤维瘤病成人患者。
2026-02-26Fosun Pharma's subsidiary obtained NMPA approval for a Phase II clinical trial of Luwomeitinib (Fumaining) combined with Anlotinib for KRAS-mutant advanced non-small cell lung cancer.复星医药子公司获国家药监局批准，开展芦沃美替尼片（复迈宁）联合安罗替尼治疗KRAS突变晚期非小细胞肺癌的II期临床试验。
2026-06-15Fosun Pharma's self-developed MEK1/2 inhibitor Luwometinib (Fu Maining) received NMPA approval for a new indication: treatment of relapsed/refractory Langerhans cell histiocytosis (LCH) in pediatric patients aged 2 years and older.复星医药自主研发的MEK1/2抑制剂芦沃美替尼（复迈宁）获国家药监局批准新适应症：用于2岁及以上复发/难治性朗格汉斯细胞组织细胞增生症（LCH）儿童患者。
Pipeline & R&D updates管线与研发进展
7 · 2024-04-23 → 2026-04-07
▾
Updates on drug pipeline, clinical trials, and R&D investments.药物管线、临床试验及研发投入的更新。
2024-04-23Fosun Pharma disclosed diabetes pipeline: insulin zinc protamine recombinant lispro mixed injection (submitted for marketing), liraglutide (Phase III), semaglutide and insulin degludec (Phase I), and early-stage oral GLP-1 and multi-target drugs.复星医药披露糖尿病管线：精蛋白锌重组赖脯胰岛素混合注射液（已提交上市）、利拉鲁肽（III期）、司美格鲁肽和德谷胰岛素（I期），以及早期口服GLP-1和多靶点药物。
2024-08-27Fosun Pharma's innovative drug revenue exceeded RMB 3.7 billion in H1 2024, with 4 innovative/biosimilar drugs and 9 indications approved domestically and overseas.复星医药2024年上半年创新药品收入超37亿元，4个创新药/生物类似药共9项适应症在境内外获批。
2025-01-15Fosun Pharma discontinued further development of FN-1501 (in-house drug) after dynamic pipeline assessment based on market value considerations.复星医药基于市场价值等因素的综合考量，决定对在研药物FN1501暂不推进后续研究。
2025-01-15Fosun Pharma paused the US Phase I clinical trial of FCN-437c for breast cancer after comprehensive assessment.复星医药经综合考量，暂停了FCN-437c在美国开展的针对乳腺癌的I期临床试验。
2025-03-12Launches self-developed PharmAID decision intelligence platform based on leading global foundational large models, covering all employees to improve efficiency and reduce costs.上线基于全球领先基础大模型自研的PharmAID决策智能体平台，覆盖全员，致力于提升工作效率、降低成本。
2025-12-30Subsidiary Chengdu Xingrui Jingxuan Biotech initiated Phase I trial in China for theranostic radiopharmaceutical project SRT-007 (Ga-68/Lu-177 PSMA) for PSMA+ metastatic castration-resistant prostate cancer.子公司成都星睿菁烜生物科技有限公司在中国启动诊疗一体化核药项目SRT-007（镓[68Ga]/镥[177Lu] PSMA）用于PSMA阳性转移性去势抵抗性前列腺癌的I期临床试验。
2026-04-07Fosun Pharma was listed among the top 25 pharma companies by pipeline scale in Citeline's Pharma R&D Annual Review 2026; 2025 R&D spending rose 6.46% to 5.913 billion yuan, with innovative drug revenue reaching 9.893 billion yuan.复星医药入选Citeline《2026年医药研发年度回顾》管线规模前25家制药公司；2025年研发总投入同比增长6.46%至59.13亿元，创新药品收入达98.93亿元。
ESG & sustainabilityESG与可持续发展
4 · 2024-04-26 → 2025-07-27
▾
ESG reports, sustainability initiatives, and related recognitions.ESG报告、可持续发展倡议及相关认可。
2024-04-26Fosun Pharma announced donation of 10 million yuan worth of artemisinin-based antimalarial drugs to Africa over three years, plus $10,000 worth of children's antimalarial drugs for Mali project.复星医药宣布未来三年向非洲捐赠价值1000万元人民币的青蒿素类抗疟药品，并向马里项目支持价值1万美元儿童抗疟药品。
2025-04-07Fosun Pharma releases its 17th annual ESG and Sustainable Development Report for 2024.复星医药发布第17份年度ESG暨可持续发展报告（2024年）。
2025-05-08Fosun Pharma officially joined the Pharmaceutical Supply Chain Initiative (PSCI) as an associate member, aligning its supply chain management with international sustainability standards.复星医药正式加入制药供应链倡议（PSCI），成为准会员，推动供应链管理与国际可持续发展标准接轨。
2025-07-27MSCI upgraded Fosun Pharma's ESG rating to AA, reflecting improved sustainability management; company invested ~RMB 110M in environmental upgrades in 2024.MSCI将复星医药的ESG评级上调至AA级，反映可持续发展管理提升；2024年公司投入约1.1亿元用于环保设施升级。
Fosun Health & elderly care expansion复星健康与养老扩张
7 · 2024-05-14 → 2025-02-20
▾
Capital increase, IPO planning, and expansion of the healthcare and elderly care business.医疗和养老业务的增资、IPO规划及扩张。
2024-05-14Subsidiary Fosun Health signed a capital increase agreement with Foshan Chancheng City Investment, which will invest RMB 300 million at a pre-investment valuation of RMB 10.2 billion, reducing Fosun Pharma's stake to 97.14%.控股子公司复星健康与佛山禅西城投签订增资协议，后者按102亿元投前估值出资3亿元，复星医药持股降至97.14%。
2024-05-14Board authorized management to initiate preliminary planning for the listing of subsidiary Fosun Health.董事会授权管理层启动控股子公司复星健康上市的前期筹划工作。
2024-05-31Subsidiary Fosun Chancheng Hospital acquired the remaining 49% stake in Foshan Xinglian Nursing Home for RMB 131,146, increasing ownership to 100%; the nursing home is expected to start operations in Q4 2024.控股子公司佛山复星禅医以13.1146万元受让佛山星莲护理院49%股权，持股增至100%；该护理院预计2024年第四季度投入运营。
2024-06-03Fosun Pharma acquired the remaining 49% equity of Foshan Xinglian Nursing Home, expanding its medical and health business.复星医药收购佛山星莲护理院剩余49%股权，扩展医疗健康业务。
2024-07-30Fosun Healthcare won the bid for the Dongxiaoma Jiayuan health and elderly care project in Tongzhou, Beijing sub-center, covering 27,700 sqm with 201 self-care rooms (353 beds) and 122 nursing rooms (223 beds).复星康养中标北京通州东小马家园康养项目，占地面积27700平米，规划自理房间201间（353张床位）和护理房间122间（223张床位）。
2024-10-29Fosun Pharma's board approved a share repurchase of 15 million yuan in registered capital from Li Shengli under the subsidiary Fosun Health's equity incentive plan, following his resignation as director.复星医药董事会批准以156.5659万元回购控股子公司复星健康离任董事李胜利已获授但尚未归属的对应150万元注册资本的跟投。
2025-02-20Subsidiary Fosun Health invested RMB 30 million to increase its stake in Shanghai Zhuorhui from 57.54% to 67.19%; Zhuorhui provides one-stop health services for mid-to-high-end clients.控股子公司复星健康出资3000万元增资上海卓尔荟，持股比例由57.54%增至67.19%；卓尔荟为中高端人士提供一站式健康服务。
Licensing & commercialization deals许可与商业化交易
16 · 2024-05-21 → 2026-07-01
▾
In-licensing and out-licensing agreements for drug rights, including upfront and milestone payments.药品权利的引进和对外许可协议，包括首付款和里程碑付款。
2024-05-21Subsidiary Henlius amended and partially terminated its license agreement with Palleon; terminated cooperation on product 1, and revised cost-sharing for early R&D of products 2 and 3 to 50% each.控股子公司复宏汉霖与Palleon修订并部分终止许可协议，终止合作产品1，产品2和3的早期研发费用改为双方各承担50%。
2024-08-21Fosun Pharma decided to terminate the bremelanotide project licensed from Palatin due to market and clinical considerations.复星医药基于市场和临床考量，决定终止从Palatin公司授权的bremelanotide项目。
2024-12-19Subsidiary Henlius signed global collaboration and license agreement with Palleon for E-602 (sialidase fusion protein) for oncology and autoimmune diseases; Henlius to conduct clinical study for lupus nephritis.子公司复宏汉霖与Palleon签订全球合作许可协议，开发E-602（唾液酸酶融合蛋白）用于肿瘤和自身免疫疾病；复宏汉霖将开展狼疮肾炎临床研究。
2025-01-14Henlius signed a license agreement with Abbott to develop and commercialize 4 biosimilars and 1 innovative biologic in 69 emerging markets across Asia, Latin America, Caribbean, and MENA; first candidates expected to launch by 2027.复宏汉霖与Abbott签署许可协议，授予其在69个新兴市场（亚洲、拉美、加勒比海、中东北非）独家或半独家开发和商业化4款生物类似药和1款生物创新药的权利；首批候选产品预计2027年上市。
2025-05-28Fosun Pharma signed an exclusive overseas commercialization deal with Jiuyuan Gene for semaglutide, Guyoudao and JY-23 in MENA, sub-Saharan Africa and select ASEAN countries.复星医药与九源基因签约，获得司美格鲁肽、骨优导和JY-23等产品在中东北非、撒哈拉以南非洲及部分东盟国家的独家临床开发、注册、生产和商业化权益。
2025-06-12Fosun Pharma and Jiuyuan Gene signed an exclusive overseas commercialization agreement for semaglutide, Guyoudao, and JY-23 in MENA, sub-Saharan Africa, and select ASEAN countries.复星医药与九源基因就司美格鲁肽、骨优导和JY-23在中东北非、撒哈拉以南非洲及部分东盟国家签署独家海外商业化协议。
2025-07-21Fosun Pharma signed an exclusive overseas commercialization deal with Jiuyuan Gene for semaglutide, Guyoudao, JY-23 and other products in MENA, sub-Saharan Africa and select ASEAN countries.复星医药与九源基因就司美格鲁肽、骨优导和JY-23等产品在中东北非、撒哈拉以南非洲及部分东盟国家签署独家海外商业化权益协议。
2025-08-26Fosun Pharma licensed global rights (ex-China, HK, Macau, Taiwan) of small-molecule inhibitor FXS6837 to Sitala for up to $190M in upfront and milestone payments, plus up to $480M in sales milestones and $5M in equity.复星医药将小分子抑制剂FXS6837除中国及港澳台地区外的全球权利授权给Sitala，可获得至多1.9亿美元首付款及里程碑付款，以及至多4.8亿美元销售里程碑和500万美元股权。
2025-08-29Fosun Pharma in-licensed exclusive rights (China, HK, Macau) of oral JAK inhibitor AC-201 from Aikenuo for autoimmune diseases, paying up to RMB 156 million in upfront and milestone payments plus sales royalties.复星医药从爱科诺引进口服JAK抑制剂AC-201在中国及港澳地区的独占权利，支付至多1.56亿元首付款及里程碑付款，并支付销售提成。
2025-10-10Expedition Therapeutics completed $165M Series A; acquired global rights (ex-China, HK, Macau) to EXPD-101 from Fosun Pharma in Aug 2025.Expedition Therapeutics完成1.65亿美元A轮融资；2025年8月从复星医药收购EXPD-101全球独家权利（不含中国大陆、香港和澳门）。
2025-10-15Suzhou Xingming Youjian (incubated by Fosun's fund) signed exclusive option agreement with UK's AviadoBio for overseas development/commercialization of optogenetic gene therapy UGX202.苏州星明优健（复星基金孵化）与英国AviadoBio就光遗传学基因疗法UGX202的海外开发与商业化签署独家选择权协议。
2025-12-09Subsidiary Yaoyou Pharma signed a license agreement with Pfizer for global exclusive rights to oral small-molecule GLP-1R agonist YP05002; upfront payment $150M, development milestones up to $350M, sales milestones up to $1.585B.子公司药友制药与辉瑞签订许可协议，授予口服小分子GLP-1R激动剂YP05002全球独家权利；首付款1.5亿美元，开发里程碑至多3.5亿美元，销售里程碑至多15.85亿美元。
2025-12-18Subsidiary Fosun Pharma Industrial signed a collaboration and option agreement with Clavis Bio to co-develop preclinical compounds; Clavis Bio has option for ex-China rights; Fosun retains China rights; up to $362.5M per project if option exercised.子公司复星医药产业与Clavis Bio签订合作及选择权协议，共同推进临床前化合物开发；Clavis Bio拥有中国以外区域的选择权，复星保留中国权益；单个项目行权后最高可获得3.625亿美元。
2026-01-28Fosun Wanbang signed an exclusive agreement with Beijing Oriental Bio for the production and commercialization of VGX-3100, a DNA drug targeting HPV16/18 for cervical precancerous lesions, in Greater China; VGX-3100 is in Phase III trials in China with all patients enrolled.复星万邦与北京东方略生物医药科技股份有限公司就VGX-3100在大中华区的生产和商业化签订独家协议；VGX-3100是靶向HPV16/18的治疗用DNA药物，用于宫颈癌前病变，在中国处于III期临床试验，已完成全部患者入组。
2026-05-28Subsidiary Yaoyou Pharmaceutical signed license agreement with Zhixiang Jintai for GR1803 (BCMAxCD3 bispecific antibody) exclusive rights in Greater China; up to 600 million yuan in payments including 300 million yuan upfront.控股子公司药友制药与智翔金泰签订许可协议，获GR1803（BCMAxCD3双特异性抗体）大中华区独占权利；付款至多6亿元，含首付款3亿元。
2026-07-01Junshi Biosciences licensed anti-IL-17A antibody Nuokaoqibei (JS005) to Fosun Pharma's subsidiary Fosun Wanbang for Greater China; Fosun pays RMB 215M upfront, up to RMB 1.125B milestones plus tiered royalties.君实生物将抗IL-17A单抗偌考奇拜单抗（JS005）在大中华区的权益授权给复星医药子公司复星万邦；首付款2.15亿元，里程碑付款最高11.25亿元，另加分级销售提成。
Henlius privatization & stake changes复宏汉霖私有化及股权变动
10 · 2024-06-24 → 2026-01-22
▾
The attempted privatization of Henlius via absorption merger, its failure, and subsequent stake increases.通过吸收合并私有化复宏汉霖的尝试、失败及后续的增持。
2024-06-24Fosun Pharma announced plan to privatize subsidiary Henlius via absorption merger; cash consideration up to ~HKD 5.407 billion at HKD 24.6/H-share, a 36.67% premium.复星医药宣布拟通过吸收合并方式私有化子公司复宏汉霖；现金对价合计不超过约54.07亿港元，每股H股24.6港元，溢价36.67%。
2024-07-03Fosun Pharma announced a plan to privatize subsidiary Henlius (02696.HK) via absorption merger, offering HKD 24.6 per H-share and HKD 22.44 per non-listed share, total consideration up to HKD 5.407 billion.复星医药宣布拟以吸收合并方式私有化子公司复宏汉霖（02696.HK），H股要约价24.6港元/股，非上市股份22.44港元/股，总对价不超过54.07亿港元。
2024-11-13Fosun Pharma's board secretary Dong Xiaoxian disclosed that the privatization of Henlius is still under review by relevant authorities, pending shareholder meetings and HKEX approval.复星医药董秘董晓娴透露，复宏汉霖私有化交易尚处于相关主管机构审核过程中，尚待股东大会和联交所批准。
2024-11-26Fosun Pharma announced that the privatization of Henlius has received approval and filing from the National Development and Reform Commission (NDRC), but still requires approvals from MOFCOM, SAFE, securities regulators, and HKEX.复星医药公告，复宏汉霖私有化交易已获国家发改委批准备案，但仍需取得商务部、国家外汇管理局、证券监管机构和联交所等批准。
2024-12-16All preconditions for the absorption merger and privatization of subsidiary Henlius have been met; comprehensive document to be sent to shareholders.子公司复宏汉霖吸收合并及私有化的所有前提条件已达成，将向股东寄发综合文件。
2024-12-22Henlius announced absorption merger proposal by Fosun New Pharma; H-share cash exit at HKD 24.6 per share; EGM set for Jan 22, 2025.复宏汉霖公告由复星新药吸收合并的提案，H股现金选择价24.6港元/股，临时股东大会定于2025年1月22日。
2025-01-22Absorption merger and privatization of Henlius failed: special resolution passed at EGM but not at H-share class meeting; Henlius retains H-share listing; Fosun holds 59.56% stake.吸收合并及私有化复宏汉霖未获通过：特别决议案在临时股东大会通过，但在H股类别股东大会未通过；复宏汉霖保留H股上市地位；复星医药持股59.56%。
2025-04-21Fosun Pharma increases stake in subsidiary Henlius (复宏汉霖) by acquiring 21.034 million unlisted shares at HKD 24.60/share for total HKD 517 million, raising its holding to 63.43%.复星医药以24.60港元/股增持复宏汉霖2103.43万股非上市股份，总价5.17亿港元，持股比例增至63.43%。
2026-01-16Fosun Pharma's subsidiary Henlius' application for full circulation of 182.65 million domestic unlisted shares (including 120 million from Fosun Pharma) to H-shares on the Hong Kong Stock Exchange completed CSRC filing.复星医药控股子公司复宏汉霖合计1.83亿股境内未上市股份（其中复星医药持有1.2亿股）申请全流通转为H股并在香港联交所上市流通，已完成中国证监会备案。
2026-01-22Fosun Pharma's subsidiary Henlius' application for full circulation of domestic unlisted shares to H-shares received CSRC filing notice; 182.65 million shares eligible for conversion.复星医药控股子公司复宏汉霖部分境内未上市股份申请全流通获中国证监会备案通知书，1.83亿股可转换为H股。
Fosun Kite (CAR-T) & Yikaida复星凯特（CAR-T）与奕凯达
8 · 2024-07-19 → 2026-04-14
▾
Ownership changes, capital increases, and clinical progress for the CAR-T joint venture and its product Yikaida.CAR-T合资企业及其产品奕凯达的股权变更、增资及临床进展。
2024-07-19Fosun Pharma Industrial and Kite Pharma signed a debt-to-equity and capital increase agreement for joint venture Fosun Kite, each contributing USD 28.5 million in existing debt converted to equity for a pro-rata capital increase.复星医药产业与Kite Pharma签订债权转股权及增资协议，分别以对合营企业复星凯特享有的2850万美元存续债权转股进行同比例增资。
2024-09-13Subsidiary Fosun Pharma Industrial agreed to acquire Kite Pharma's 50% stake in Fosun Kite for USD 27 million, gaining 100% ownership, and will inject an additional USD 10 million; Fosun Kite to be renamed Fosun Kairui and obtains exclusive rights to develop, manufacture and commercialize Yikaida and Brexu-Cel in China, Hong Kong and Macau.控股子公司复星医药产业拟以2700万美元受让Kite Pharma持有的复星凯特50%股权，实现100%控股，并增资1000万美元；复星凯特拟更名为复星凯瑞，获许可在中国内地、香港和澳门独家开发、生产及商业化奕凯达®及Brexu-Cel。
2024-10-24Fosun Pharma announced it will participate in the 7th China International Import Expo (CIIE) as a seven-time exhibitor, showcasing innovative drugs and devices including CAR-T product Axi-Cel (Yikaida), Ion bronchoscopy robot, and Da Vinci surgical robot.复星医药宣布将作为七届全勤展商参加第七届中国国际进口博览会，展示包括CAR-T产品阿基仑赛注射液（奕凯达）、Ion支气管镜机器人和达芬奇手术机器人等创新药械。
2024-11-10At the CIIE, Fosun Pharma highlighted that CAR-T cell therapy Yikaida (Axicabtagene Ciloleucel) has been used to treat over 900 lymphoma patients across 170 high-standard treatment centers in 28 provinces.在进博会上，复星医药强调CAR-T细胞疗法奕凯达（阿基仑赛注射液）已在全国28个省区市170家高标准治疗中心治疗超过900位淋巴瘤患者。
2025-10-17Shenzhen Biomedical Industry Fund to invest RMB 600M in Fosun Kairui (CAR-T unit) Series A; 14 key employees to invest RMB 3.525M; Fosun's stake to drop from 97.78% to ~77.10%.深圳生物医药产业基金拟出资6亿元参与复星凯瑞A轮融资；14名核心员工跟投352.5万元；复星持股比例由97.78%降至约77.10%。
2025-11-10Fosun Kite (Fosun Pharma subsidiary) signed MOU with Saudi Fakeeh Care Group to collaborate on CAR-T cell therapy clinical implementation and localized production in Saudi Arabia.复星凯瑞与沙特Fakeeh Care Group签署合作备忘录，共同推进CAR-T细胞治疗在沙特的临床落地和本地化生产。
2026-01-14Fosun Kairui obtained exclusive commercialization rights in China for AlloJoin (allogeneic human adipose-derived mesenchymal stem cell injection) from Sibiman Biotech, a product in Phase III clinical trials for osteoarthritis.复星凯瑞获得思比曼生物异体人源脂肪间充质干细胞注射液洛它阿托赛（AlloJoin）在国内独家商业化权益，该产品处于骨关节炎III期临床试验。
2026-04-14Subsidiary Fosun Kite received NMPA approval for Phase I/II trial of FKC289 (BCMA/CD19-targeted CAR-T) for relapsed/refractory primary light chain amyloidosis and membranous nephropathy; cumulative R&D investment ~59 million yuan.子公司复星凯瑞获国家药监局批准，开展FKC289（靶向BCMA和CD19的CAR-T细胞产品）I/II期临床试验，用于复发/难治原发性轻链淀粉样变及膜性肾病；累计研发投入约0.59亿元。
Botulinum toxin (Daxifei/RT002) launch肉毒杆菌毒素（达希斐/RT002）上市
6 · 2024-08-16 → 2025-07-09
▾
Approval, launch preparation, and new indication for the injectable botulinum toxin type A.注射用A型肉毒毒素的获批、上市准备及新适应症。
2024-08-16Fosun Pharma's partner Revance Therapeutics was acquired by Crown Laboratories for $924 million; Fosun holds exclusive commercialization rights for RT002 (DAXXIFY) in Greater China since 2018.复星医药合作伙伴Revance Therapeutics被Crown Laboratories以9.24亿美元收购；复星自2018年起拥有RT002（DAXXIFY）在大中华区的独家商业化权利。
2024-09-09Subsidiary Fosun Pharma Industrial obtained NMPA marketing approval for injectable Botulinum Toxin Type A (DAXXIFY) to temporarily improve moderate-to-severe glabellar lines in adults.控股子公司复星医药产业获国家药监局批准，注射用A型肉毒毒素（达希斐®）上市，用于暂时性改善成人中度至重度眉间纹。
2024-10-10Fosun Pharma stated it is actively promoting the launch of its botulinum toxin product (trademark: Daxifei) for injection in China, pending import customs clearance procedures.复星医药表示，正在积极推动其注射用A型肉毒毒素产品（商标：达希斐）在中国境内上市销售，尚需完成入关申报等流程。
2024-11-13Fosun Pharma's CFO Chen Zhanyu stated at the performance briefing that the injectable botulinum toxin type A (Daxibei) still needs to complete import customs declaration procedures per regulations.复星医药首席财务官陈战宇在业绩说明会上表示，注射用A型肉毒毒素（达希斐）尚需按进口药品注册要求完成入关申报流程。
2024-11-27Fosun Pharma's subsidiary Fosun Pharma Industrial received NMPA approval for a new indication of injectable botulinum toxin type A (Daxibei, RT002) for the treatment of adult cervical dystonia.复星医药控股子公司复星医药产业获国家药监局批准，注射用A型肉毒毒素（达希斐，RT002）新适应症用于治疗成人颈部肌张力障碍。
2025-07-09Company confirmed it is advancing pre-launch preparations for botulinum toxin type A for injection (trademark: Daxifei) in China, approved 10 months ago.公司确认正在全力推进注射用A型肉毒毒素（中国境内商标：达希斐）在中国上市销售前的各项准备工作，该产品已于10个月前获批。
Corporate governance & compliance公司治理与合规
8 · 2024-08-19 → 2025-12-08
▾
Governance document revisions, regulatory letters, and compliance-related matters.治理文件修订、监管函件及合规相关事项。
2024-08-19Fosun Pharma announced its first extraordinary general meeting of 2024 to be held on September 27, 2024, to elect non-executive directors.复星医药宣布2024年第一次临时股东大会将于2024年9月27日召开，审议选举非执行董事的议案。
2025-06-25Fosun Pharma revised multiple governance documents including cumulative voting rules, shareholder meeting rules, independent director system, and board committee rules.复星医药修订累积投票制实施细则、股东会议事规则、独立非执行董事制度及董事会各专门委员会细则等多项治理文件。
2025-06-25Fosun Pharma adopted a co-investment management method for key subsidiaries/projects, covering core decision teams and employees.复星医药发布跟投管理办法，适用于对集团发展有重要影响的控股及参股企业/项目。
2025-06-25Fosun Pharma revised its related-party transaction management system, clarifying transaction classification, review procedures, and disclosure requirements.复星医药修订关联交易管理制度，明确交易分类、审议程序及披露要求。
2025-06-25Fosun Pharma revised its information disclosure management system, strengthening internal approval procedures and insider registration.复星医药修订信息披露管理制度，强化内部审批流程及内幕信息知情人登记。
2025-06-25Fosun Pharma revised its fundraising management system, requiring funds to be used primarily for main business and strengthening supervision.复星医药修订募集资金管理制度，要求资金原则上用于主营业务并强化监管。
2025-06-25Fosun Pharma revised its board secretary work system, clarifying selection, duties, and assessment mechanisms.复星医药修订董事会秘书工作制度，明确选任、履职及考核机制。
2025-12-08NMPA announced two batches of coenzyme Q10 injection from subsidiary Wanbang Pharmaceutical failed inspection (appearance, particulate matter, visible particles).国家药监局通告子公司万邦医药两批次辅酶Q10注射液不符合规定（性状、不溶性微粒、可见异物）。
Financing & debt instruments融资与债务工具
9 · 2025-03-25 → 2026-02-26
▾
Issuance of bonds, notes, credit facilities, and other financing activities.债券、票据、信贷额度及其他融资活动。
2025-03-25Receives acceptance registration from NAFMII for medium-term notes (RMB 4 billion) and ultra-short-term commercial paper (RMB 6 billion), valid for 2 years from March 20, 2025, jointly lead underwritten by Bank of Shanghai and China Merchants Bank.收到中国银行间市场交易商协会《接受注册通知书》，中期票据注册金额40亿元、超短期融资券注册金额60亿元，自2025年3月20日起2年内有效，由上海银行和招商银行联席主承销。
2025-03-25Overseas subsidiary Gland Pharma authorized to invest Indian mutual funds and/or bonds (government or corporate) with a maximum daily balance of INR 20 billion (approx. RMB 1.644 billion).境外控股子公司Gland Pharma获授权投资印度当地共同基金及/或债券，单日最高投资余额不超过等值200亿印度卢比（约16.44亿元人民币）。
2025-03-25Plans to conduct sale-and-leaseback financing for some subsidiaries using self-owned equipment assets, with total financing not exceeding RMB 1.2 billion.部分控股子公司拟以自有设备资产开展售后回租融资租赁业务，融资总额不超过12亿元。
2025-04-27Fosun Pharma completes issuance of 2025 first tranche medium-term note (Sci-Tech Innovation Note) of RMB 500 million, 2-year term, at 3.10% interest rate.复星医药完成发行2025年度第一期中期票据（科创票据），实际发行总额5亿元，期限2年，利率3.10%。
2025-06-24Fosun Pharma's 2024 AGM approved a new credit facility of up to RMB 50 billion and renewal of guarantee limits.复星医药2024年度股东会批准新增不超过500亿元授信额度及续展担保额度。
2025-07-09Company and its subsidiaries fully repaid RMB 410M of temporarily borrowed idle proceeds from the 2022 private placement to the special accounts by July 7, 2025.公司及募投实施主体已于2025年7月7日前将此前用于暂时补充流动资金的4.1亿元闲置募集资金全部归还至募集资金专项账户。
2025-08-07Fosun Pharma completed the issuance of the 2025 second tranche of sci-tech innovation bonds (MTN002) for RMB 1 billion, with a 2-year term and a coupon rate of 2.70%.复星医药完成2025年度第二期科技创新债券（MTN002）发行，总额10亿元，期限2年，票面利率2.70%。
2025-12-242022 private placement fundraising projects all completed and special accounts closed; total net proceeds of ~CNY 4.456B fully utilized.2022年非公开发行募投项目全部结项，专户完成销户；募集资金净额约44.56亿元已全部使用完毕。
2026-02-26Fosun Pharma received CSRC approval to issue up to RMB 6 billion in science and technology innovation corporate bonds to professional investors, valid for 24 months.复星医药获中国证监会批复，同意向专业投资者公开发行不超过60亿元人民币的科技创新公司债券，有效期24个月。
Fosun Pharma Industry (subsidiary) actions复星医药产业（子公司）动态
6 · 2025-07-28 → 2026-05-26
▾
Clinical trials, approvals, and licensing activities specifically for the Fosun Pharma Industrial subsidiary.专属于复星医药产业子公司的临床试验、获批及许可活动。
2025-07-28Subsidiary Fosun Pharma Industrial signed license agreement with NewCo for AR1001 (PDE-5 inhibitor for Alzheimer's) in China, HK and Macau; up to RMB 150M upfront and regulatory milestones; global Phase III ongoing.子公司复星医药产业与纽科就AR1001（PDE-5抑制剂，用于阿尔茨海默病）在中国内地及港澳地区签署许可协议，首付款及监管里程碑款最高1.5亿元，全球Ⅲ期临床试验进行中。
2025-12-15Subsidiary Fosun Pharma Industrial plans to invest ~CNY 1.412B to acquire 53% controlling stake in Green Valley Pharma, whose core asset is the Alzheimer's drug sodium oligomannate (GV-971); the drug's conditional approval certificate expired Nov 2024 and post-market confirmatory trial is ongoing.子公司复星医药产业拟出资约14.12亿元控股收购绿谷医药53%股权，其核心资产为阿尔茨海默病药物甘露特钠胶囊（GV-971）；该药有条件批准证书于2024年11月到期，上市后确证性临床试验正在进行中。
2026-01-05Fosun Pharma announced a 1.412 billion yuan acquisition to control Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd., taking over the clinical and commercialization of sodium oligomannate capsules (GV-971) for Alzheimer's disease, which had been suspended due to expired registration; the Shanghai Stock Exchange issued a regulatory inquiry.复星医药宣布以14.12亿元收购控股绿谷（上海）医药科技有限公司，承接甘露特钠胶囊（GV-971）的后续临床与上市推进工作，该品种因注册批件到期暂停销售；上交所发出监管问询。
2026-03-24Fosun Pharma and Teva jointly developed FXB0871; licensed-in multiple overseas original drugs including Aokangze, Puruini, and Daxifei which were approved for marketing in China.复星医药与Teva联合开发FXB0871；通过许可引进方式引入奥康泽、普瑞尼、达希斐等多款境外原研药并实现中国境内获批上市。
2026-05-13Subsidiary Fosun Pharma Industry signed exclusive option agreement with AriBio for AR1001 (early Alzheimer's disease); $60 million option fee, up to $180 million upfront and milestone payments upon exercise.控股子公司复星医药产业与AriBio签订AR1001（早期阿尔茨海默病）独家选择权协议；选择权费6000万美元，行权后首付款及里程碑付款至多1.8亿美元。
2026-05-26Subsidiary Fosun Pharma Industry to invest ~414 million yuan in Xingyao Kunze's Series B round and share transfer, acquiring 20.87% stake; company focuses on liver disease innovative drugs.控股子公司复星医药产业拟出资约4.14亿元参与星曜坤泽B轮融资及股权转让，获得20.87%股权；该公司专注于肝病创新药研发。
Xinghao Pengbo (XH-S004/XH-S003) development星浩澎博（XH-S004/XH-S003）开发
1 · 2025-08-11
▾
Clinical development of XH-S004 and XH-S003 for various indications.XH-S004和XH-S003针对多种适应症的临床开发。
2025-08-11Fosun Pharma licensed global rights (ex-China, HK, Macau) of oral DPP-1 inhibitor XH-S004 to Expedition for up to $120M in upfront and milestone payments, plus up to $525M in sales milestones and royalties.复星医药将口服DPP-1抑制剂XH-S004除中国及港澳地区外的全球权利授权给Expedition，可获得至多1.2亿美元首付款及里程碑付款，以及至多5.25亿美元销售里程碑和特许权使用费。
